var title_f34_55_35696="Enlarged nuchal translucency";
var content_f34_55_35696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enlarged nuchal translucency measuring 5.1 mm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lynn Simpson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35696=[""].join("\n");
var outline_f34_55_35696=null;
var title_f34_55_35697="Pelvic lymphadenectomy4";
var content_f34_55_35697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transect distal end of left obturator nodes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35697=[""].join("\n");
var outline_f34_55_35697=null;
var title_f34_55_35698="Oral cavity anatomy";
var content_f34_55_35698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Oral cavity anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35698=[""].join("\n");
var outline_f34_55_35698=null;
var title_f34_55_35699="Oropharynx anatomy";
var content_f34_55_35699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the oropharynx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35699=[""].join("\n");
var outline_f34_55_35699=null;
var title_f34_55_35700="Nystatin (topical): Patient drug information";
var content_f34_55_35700=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nystatin (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14963?source=see_link\">",
"     see \"Nystatin (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/24/16771?source=see_link\">",
"     see \"Nystatin (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9490179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nyamyc&reg;;",
"     </li>",
"     <li>",
"      Nystop&reg;;",
"     </li>",
"     <li>",
"      Pedi-Dri&reg;;",
"     </li>",
"     <li>",
"      Pediaderm&trade; AF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9490180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Candistatin&reg;;",
"     </li>",
"     <li>",
"      Nyaderm",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nystatin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug if you have belly pain, fever, or bad-smelling discharge. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the yeast infection keeps coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sprinkle powder over affected skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695159",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using for athlete's foot, you may sprinkle in shoes and socks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use tablet vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12268 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-3A022BFF98-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35700=[""].join("\n");
var outline_f34_55_35700=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490179\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9490180\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024394\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024393\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024398\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024399\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024401\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024396\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024397\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024402\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024403\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/17/11539?source=related_link\">",
"      Nystatin (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/63/40947?source=related_link\">",
"      Nystatin (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/52/14147?source=related_link\">",
"      Nystatin (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14963?source=related_link\">",
"      Nystatin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/24/16771?source=related_link\">",
"      Nystatin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_55_35701="Nesiritide in the treatment of acute decompensated heart failure";
var content_f34_55_35701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nesiritide in the treatment of acute decompensated heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35701/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35701/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35701/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35701/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35701/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35701/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35701/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/55/35701/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute decompensated heart failure (HF) is a common and potentially fatal cause of acute respiratory distress. The clinical syndrome is characterized by the development of dyspnea which is commonly associated with the rapid accumulation of fluid within the lung's interstitial and alveolar spaces due to acutely elevated cardiac filling pressures (cardiogenic pulmonary edema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute decompensated HF can also present as elevated left ventricular filling pressures and dyspnea without pulmonary edema.",
"   </p>",
"   <p>",
"    Multiple modalities are used in the treatment of acute decompensated HF, including oxygen, diuretics, vasodilators, and, in selected patients, inotropic agents.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    (recombinant human brain natriuretic peptide, BNP 1-32) is a vasodilator that has undergone clinical trials in patients with acute HF.",
"   </p>",
"   <p>",
"    The possible role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    in the management of acute decompensated HF will be reviewed here. General issues related to the management of acute decompensated HF, the pathophysiology and evaluation of patients with this disorder, and the management of chronic systolic and diastolic HF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although plasma brain natriuretic peptide (BNP) levels are increased in patients with HF, such patients are sodium avid and have increased systemic vascular resistance. This apparent paradox may be caused by lack of specificity of commercially available immunoreactive-BNP assays which measure inactive as well as active forms; bioactive BNP 1-32 levels may be low in patients with HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, patients with HF have high levels of vasoconstrictors, particularly angiotensin II and norepinephrine, which may overcome BNP&rsquo;s effects. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=see_link\">",
"     \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    The high level of vasoconstrictors and high systemic vascular resistance and possibly low levels of bioactive BNP in these patients provides the rationale for therapy with vasodilators, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    . Infusion of nesiritide at doses of up to 0.1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min in patients with HF can raise the mean plasma BNP concentration from 700 to 13,000",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    with associated arterial and venous vasodilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    acutely reduced pulmonary capillary wedge pressure and dyspnea in patients with acute decompensated HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, the largest randomized controlled trial found that nesiritide only slightly reduced dyspnea (with borderline significance), did not alter rates of death or rehospitalization, and significantly increased rates of hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Effect on hemodynamics and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies demonstrated the acute hemodynamic effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In the larger study, 489 patients, including 246 who underwent pulmonary artery catheterization, were assigned to nesiritide, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , or placebo for three hours, followed by nesiritide or intravenous nitroglycerin for 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/5\">",
"     5",
"    </a>",
"    ]. Nesiritide decreased the mean pulmonary capillary wedge pressure significantly more than either intravenous nitroglycerin or placebo at three hours (5.8 versus 3.8 and 2.0 mmHg) and significantly more than nitroglycerin at 24 hours (8.2 versus 6.3 mmHg). However, the dose of nitroglycerin given tended to be less than that used clinically. Dyspnea was reduced and global clinical status was improved when compared with placebo, but there was no significant difference for either parameter compared to intravenous nitroglycerin.",
"   </p>",
"   <p>",
"    In the largest randomized placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    in acute heart failure (ASCEND-HF, n = 7141), nesiritide produced only a small improvement in dyspnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/6\">",
"     6",
"    </a>",
"    ]. Findings included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       Nesiritide",
"      </a>",
"      slightly increased the frequency of markedly or moderately improved dyspnea at six hours (44.5 versus 42.1 percent, p = 0.03) and 24 hours (68.2 versus 66.1 percent, p = 0.007). This small improvement was significant according to the prespecified level required by the European Medicine Agency (p&le;0.05 for both assessments or p&le;0.025 for either) but did not meet the prespecified level for significance required by United States regulators because of the multiple comparisons performed in the trial (p&le;0.005 for both assessments or p&le;0.0025 for either).",
"     </li>",
"     <li>",
"      Hypotension was significantly more frequent in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      group compared to the placebo group (26.6 versus 15.3 percent). Symptomatic (7.2 versus 4.0 percent) as well as asymptomatic (21.4 versus 12.4 percent) hypotension was increased.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect on mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    use in acute decompensated HF does not improve or worsen the 30-day mortality rate. A trend toward increase in 30-day mortality among patients receiving nesiritide was observed in a meta-analysis of three randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/7\">",
"     7",
"    </a>",
"    ] but not in a later meta-analysis of seven randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, the ASCEND-HF trial of 7141 patients with acute HF found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    had no effect on 30-day mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect on renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have yielded conflicting results on the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    therapy on renal function in acute decompensated HF, but the largest trial found no effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ]. There is no evidence for improved renal function and data are conflicting on whether there is a modest natriuresis and diuresis with nesiritide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/3,4,9,11,12\">",
"     3,4,9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concern for risk of renal dysfunction was raised by a meta-analysis that included 1269 patients with HF treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/9\">",
"     9",
"    </a>",
"    ], but no effect on renal function was found in the ASCEND-HF trial. The ASCEND-HF trial of nesiritide versus placebo in 7141 patients with acute HF found that nesiritide therapy (continuous infusion at 0.01",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per min with an initial loading dose of 2",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    at the investigator&rsquo;s discretion) did not increase or decrease the risk of worsening renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of vasodilators generally on renal function is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=see_link&amp;anchor=H17931536#H17931536\">",
"     \"Cardiorenal syndrome: Prognosis and treatment\", section on 'Vasodilators'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available evidence does",
"    <strong>",
"     not",
"    </strong>",
"    support routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    in patients hospitalized with acute decompensated heart failure. We recommend against the routine use of nesiritide in such patients. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In carefully selected patients hospitalized with acute HF with appropriate hemodynamics (without hypotension or cardiogenic shock) who remain symptomatic despite routine therapy, a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    may be helpful as an alternative to other vasodilator therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    ). As noted above, in one study nesiritide produced greater reductions in pulmonary capillary wedge pressure compared to low doses of intravenous nitroglycerin, although the effect on symptoms was similar (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Effect on hemodynamics and symptoms'",
"    </a>",
"    above). The relative merits of nesiritide in relation to other intravenous agents for HF (vasodilators such as nitroprusside and nitroglycerin or other agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    , and dopamine) remain uncertain. Nesiritide has a longer effective half-life than nitroglycerin or nitroprusside, so side effects such as hypotension may persist longer.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    is used, close monitoring of hemodynamics, urine output, and renal function is necessary. The risk of hypotension appears to be dose related.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    is given as a continuous infusion of 0.01",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min which is generally preceded by an initial intravenous bolus of 2",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. The dose is increased if, after 3 to 24 hours, the desired therapeutic response (an increase in urine output, symptomatic improvement, and, in invasively monitored patients, a reduction in cardiac filling pressures) is not achieved. When an increased dose is necessary, the infusion is usually increased by 0.005",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min, preceded by a bolus of 1",
"    <span class=\"nowrap\">",
"     mcg/kg,",
"    </span>",
"    up to a maximum of 0.03",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per min.",
"   </p>",
"   <p>",
"    If hypotension occurs, the infusion should be discontinued.",
"   </p>",
"   <p>",
"    There is no need for dose adjustment for renal dysfunction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     Nesiritide",
"    </a>",
"    infusion at any dose can be discontinued without tapering. The hemodynamic effects persist for 6 to 24 hours; as a result, close observation of the patient's hemodynamic status and urine output should continue during this period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     BNP monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma BNP should NOT be used for clinical assessment during the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    (BNP 1-32), since nesiritide will be detected as an increase in plasma BNP concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. As noted above, commercially available immunoreactive-BNP assays measure inactive and active forms of BNP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the assay for the N-terminal fragment of pro-BNP (N-pro-BNP) does not detect",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35701/abstract/14\">",
"     14",
"    </a>",
"    ]. As a result, this assay could be used to assess the response to therapy, although there are no published data to support this approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Additional medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    , physicians need to consider how to manage other components of acute HF therapy (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: Components of therapy\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous loop diuretics are typically continued during",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      therapy.",
"     </li>",
"     <li>",
"      ACE inhibitors can be given in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      . However, if hypotension limits therapy, we favor continuation of ACE inhibitor therapy over initiation of nesiritide.",
"     </li>",
"     <li>",
"      As discussed above, in selected patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      is a reasonable alternative to other vasodilator therapy although comparative data are limited. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Use'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Vasodilator therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with acute HF,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      increases rates of hypotension, does not alter rates of death or rehospitalization at 30 days, and shows a borderline significant trend toward reducing dyspnea. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effect on hemodynamics and symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect on mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials have yielded conflicting results on the effect of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      therapy on renal function in the treatment of acute decompensated HF. The largest trial, ASCEND-HF, found no change in risk of worsening renal function. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effect on renal function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients hospitalized with acute heart failure (HF), we recommend",
"      <strong>",
"       not",
"      </strong>",
"      treating with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In carefully selected patients with appropriate hemodynamics (without hypotension or cardiogenic shock) who remain symptomatic despite routine therapy, a trial of nesiritide may be helpful as an alternative to other vasodilator therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      ). Nesiritide has a longer effective half-life than nitroglycerin or nitroprusside, so side effects such as hypotension may persist longer. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Use'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of acute decompensated heart failure: Components of therapy\", section on 'Vasodilator therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recommendations for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33029?source=see_link\">",
"       nesiritide",
"      </a>",
"      use in the treatment of acute decompensated HF must be made in the context of other therapeutic considerations. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: General considerations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/1\">",
"      Ware LB, Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005; 353:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/2\">",
"      Niederkofler EE, Kiernan UA, O'Rear J, et al. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail 2008; 1:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/3\">",
"      Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/4\">",
"      Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/5\">",
"      Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/6\">",
"      O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/7\">",
"      Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/8\">",
"      Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J 2006; 152:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/9\">",
"      Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/10\">",
"      Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2007; 50:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/11\">",
"      Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 2004; 110:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/12\">",
"      Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/13\">",
"      Nesiritide for decompensated congestive heart failure. Med Lett Drugs Ther 2001; 43:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35701/abstract/14\">",
"      Heublein DM, Huntley BK, Boerrigter G, et al. Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 2007; 49:1114.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3474 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35701=[""].join("\n");
var outline_f34_55_35701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Effect on hemodynamics and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect on mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect on renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BNP monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Additional medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/26/44456?source=related_link\">",
"      Cardiorenal syndrome: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34698?source=related_link\">",
"      Treatment of acute decompensated heart failure: Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_55_35702="Umbilical cord blood acid-base analysis";
var content_f34_55_35702=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Umbilical cord blood acid-base analysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35702/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35702/contributors\">",
"     Edward R Yeomans, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35702/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35702/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35702/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35702/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35702/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/55/35702/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal acid-base balance can be assessed in a number of ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical cord blood sampling immediately after delivery",
"     </li>",
"     <li>",
"      Antepartum umbilical cord blood sampling (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"       \"Fetal blood sampling\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fetal scalp blood assessment (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=see_link&amp;anchor=H24#H24\">",
"       \"Intrapartum fetal heart rate assessment\", section on 'Fetal scalp blood sampling'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Umbilical cord blood analysis for evaluation of the newborn's acid-base status immediately after delivery is the most objective way of assessing the fetal metabolic condition at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This information can also be useful from medical and medicolegal perspectives since it provides insight into intrapartum fetal physiology and, if normal, excludes perinatal asphyxia or hypoxia secondary to the birth process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, only a minority of newborns who have low Apgar scores are acidotic at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], which suggests that the depression is related to factors other than prolonged hypoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Umbilical cord blood pH and gas values assessed immediately after delivery will be reviewed here. Fetal acid-base physiology is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1253?source=see_link\">",
"     \"Fetal acid-base physiology\"",
"    </a>",
"    .) A general review of acid-base balance can also be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9173?source=see_link\">",
"     \"Chapter 10A: Acids and bases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding indications for umbilical cord blood acid-base analysis postdelivery. We feel it is reasonable to perform this test in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe intrauterine growth restriction, multifetal gestations, intrapartum fever, maternal thyroid disease, breech deliveries, and preterm births [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1,3\">",
"       1,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Births complicated by meconium staining, an abnormal fetal heart rate pattern, or low five-minute Apgar scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1,3,8\">",
"       1,3,8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Royal College of Obstetricians and Gynecologists and the Royal College of Midwives, recommend that cord blood acid-base analysis be \"considered\" for all deliveries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/9\">",
"     9",
"    </a>",
"    ], a practice followed by some clinicians in the United States as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 10 to 20 cm segment of umbilical cord is doubly clamped as soon as possible after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1,3,8,10\">",
"     1,3,8,10",
"    </a>",
"    ] because delay in clamping may significantly affect pH and gas values as a result of gaseous diffusion and continuing metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Blood is drawn from the umbilical artery into a 1 to 2 mL syringe, which has been flushed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and the syringe is immediately transported on ice to the laboratory. As with maternal arterial blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/13\">",
"     13",
"    </a>",
"    ], most studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/14-17\">",
"     14-17",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/10\">",
"     10",
"    </a>",
"    ], have shown that a cord blood sample in a syringe flushed with heparin and kept on ice is reasonably stable for assessment of both pH and base deficit for 60 minutes. Therefore a sample may be obtained immediately and held until a decision is made for or against these tests. Ideally, the test is performed as soon as possible after delivery. Delayed sampling from a clamped umbilical cord at room temperature up to 90 minutes after birth has been used to estimate the arterial pH and base excess at birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/18\">",
"     18",
"    </a>",
"    ]. The estimate is based on studies reporting the rate of fall of pH over time (eg, cord pH falls 0.05 at 30 minutes, 0.087 at 60 minutes, and 0.112 at 90 minutes after birth).",
"   </p>",
"   <p>",
"    If difficulty is encountered in obtaining umbilical cord artery blood samples, the vessels on the fetal surface of the placenta can be utilized (\"arteries cross over veins\") and will provide similar, but not necessarily equivalent, results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/10,19,20\">",
"     10,19,20",
"    </a>",
"    ]. Some clinicians prefer to obtain a sample from both the artery and vein, although the cost-effectiveness for this practice has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/21\">",
"     21",
"    </a>",
"    ]. If both vessels are sampled, the median arteriovenous pH difference is 0.09 (range 0.02-0.49). If only one sample is to be obtained it is generally recommended that the umbilical artery be sampled, as this usually provides the most accurate information on the acid-base status of the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1,22,23\">",
"     1,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pH, PCO2, PO2, CO2, hemoglobin, and oxygen content of the blood can be measured. Bicarbonate concentration, percentage oxygen saturation, and base excess (or deficit) are calculated. The most useful values for interpretation of fetal-newborn condition and prognosis are the pH and base excess (or deficit) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NORMAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean umbilical blood pH and gas values for premature and term infants are almost identical, although the premature infant may have low Apgar scores because of prematurity itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/19,24,25\">",
"     19,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal pH is normally 0.1 unit lower than maternal pH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preterm infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean umbilical artery blood pH and gas values for preterm infants are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef69589 \" href=\"mobipreview.htm?0/23/379\">",
"     table 1",
"    </a>",
"    ). A good approximation of the normal range for pH was demonstrated in a large study of over 1000 preterm infants delivered vaginally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/19\">",
"     19",
"    </a>",
"    ]. The mean arterial pH, 5th and 95th percentiles were 7.28, 7.14 and 7.40, respectively.",
"   </p>",
"   <p>",
"    Neither table in this topic contains data regarding the partial pressure of oxygen (paO",
"    <sub>",
"     2",
"    </sub>",
"    ) or oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ) in the umbilical artery.&nbsp;Despite initial expectations that assessment of fetal pulse oximetry would be clinically important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/26\">",
"     26",
"    </a>",
"    ], the largest US trial confirmed that knowledge of fetal oxygen saturation is not associated with a reduction in the rate of cesarean delivery or with improvement in the condition of the newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/27\">",
"     27",
"    </a>",
"    ]. For now, umbilical cord blood acid-base analysis should be confined to the parameters shown in the tables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Term infant",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean umbilical artery blood pH and gas values for term infants are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef50916 \" href=\"mobipreview.htm?0/19/315\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/19,24,28,29\">",
"     19,24,28,29",
"    </a>",
"    ]. A series including over 3500 term newborns delivered vaginally reported the mean arterial pH, 5th and 95th percentiles were 7.27, 7.15, and 7.38, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one review, the mean(SD) for umbilical cord blood gas values obtained at cesarean delivery for term pregnancies not in labor were umbilical artery pH 7.27(0.04), umbilical artery pCO",
"    <sub>",
"     2",
"    </sub>",
"    49(9) mmHg, and umbilical artery base excess -4(3)",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    with slight variations from these values depending on type of anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FETAL ACIDEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 51 cohort and case-control studies including a total of 481,753 infants found a relationship between cord pH &lt;7.00 to 7.24 at birth and several adverse neonatal and long-term outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/23\">",
"     23",
"    </a>",
"    ]. However, such a broad range of pH overlaps substantially with the lower limit of normal and thus is not clinically useful. A more useful concept would be to adopt a range of pH such as 6.95 to 7.05 (see below) rather than a single cutoff. An important contribution of the metaanalysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/23\">",
"     23",
"    </a>",
"    ] is that, even with the broad range of &lt;7.0 to 7.24, the authors verified a strong association between cord arterial pH and a number of clinically important neonatal outcomes: neonatal mortality (OR 16.9, 95% CI 9.7-29.5), hypoxic ischemic encephalopathy (OR 13.8, 95% CI 6.6-28.9), intraventricular hemorrhage or periventricular leukomalacia (OR 2.9, 95% CI 2.1-4.1), and cerebral palsy (OR 2.3, 95% CI 1.3-4.2).",
"   </p>",
"   <p>",
"    An exact cutoff to define \"significant\" acidemia cannot be determined from the literature and that accounts for our suggested range of 6.95 to 7.05. A workable threshold employed by several investigators for significant or \"pathologic fetal acidemia\" is 7.00 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/31-36\">",
"     31-36",
"    </a>",
"    ], which occurs in 3.7 per 1000 nonanomalous term births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/37\">",
"     37",
"    </a>",
"    ]. Support for use of this threshold can be derived, in part, from a systematic review of studies of nonanomalous term births with pH less than 7.0 in developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/37\">",
"     37",
"    </a>",
"    ]. The overall incidence of neonatal neurologic morbidity or mortality was 23.1 percent: survival with neonatal neurologic morbidity occurred in 51 of 297 infants (17.2 percent), seizures occurred in 45 of 276 (16.3 percent), and neonatal death occurred in 24 of 407 (5.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/37\">",
"     37",
"    </a>",
"    ]. It should be noted, however, that the majority of newborns with pH less than 7.00 will be admitted to the regular newborn nursery and have an uncomplicated neonatal course, and no increased risk for neurologic or behavioral problems when followed to school age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of neonatal morbidity is inversely related to pH with the highest risk at the lowest pHs, especially less than 6.9. A study that correlated umbilical artery blood gas parameters with death and indicators of morbidity in neonates with pathologic fetal acidemia (pH &lt;7.0) reported that a lower umbilical artery pH was significantly associated with hypoxic-ischemic encephalopathy (6.69 versus 6.93), cardiopulmonary resuscitation (6.83 versus 6.93), seizure (6.75 versus 6.93), intubation (6.83 versus 6.94), and intrauterine growth restriction (6.72 versus 6.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Umbilical artery PO2 is not predictive of any adverse neonatal outcome. Newborns with hypoxia proximate to delivery that might result in subsequent neurologic injury should manifest the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Umbilical artery blood pH &lt; 7.00",
"     </li>",
"     <li>",
"      A metabolic component",
"     </li>",
"     <li>",
"      Apgar scores of &le; 3 for &gt; 5 minutes",
"     </li>",
"     <li>",
"      Seizures, coma, hypotonia",
"     </li>",
"     <li>",
"      Evidence of multisystem organ dysfunction in neonatal period",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Respiratory acidosis alone is not usually associated with complications in the newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Base deficit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic acidosis results in excess production of acid and decreased buffer base, which is referred to as the base deficit or negative base excess. Base deficit does not significantly change during respiratory acidosis.",
"   </p>",
"   <p>",
"    In the series discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/39\">",
"     39",
"    </a>",
"    ], the metabolic component of fetal acidemia (ie, base deficit and bicarbonate) was the most important variable for predicting neonatal morbidity. This was illustrated in another study that found moderate and severe newborn encephalopathy, respiratory complications, and composite complication scores &gt;3 were increased in newborns with an umbilical artery base deficit greater than 12 to 16",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    compared to those with lower base deficits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/42\">",
"     42",
"    </a>",
"    ]. The risk of moderate or severe newborn complications in newborns with umbilical artery base deficit greater than 16",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    was fourfold higher than in those at 12 to 16",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    (40 and 10 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/43\">",
"     43",
"    </a>",
"    ]. Others have confirmed that base deficit greater than 12",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    is a reasonable threshold for prediction of neonatal complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group expressed concern that relying solely on the base deficit could miss important acid-base abnormalities in complex disturbances encountered during labor and delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/45\">",
"     45",
"    </a>",
"    ]. The authors of that report sought to establish reference values for \"strong ion difference\" (SID) in umbilical venous blood. SID may permit a more comprehensive approach to acid-base abnormalities in the newborn. SID is defined as (Na+K+Mg+Ca)-(Cl+lactate). No studies have been conducted to relate SID results to neonatal complications.",
"   </p>",
"   <p>",
"    In general, the incidence and severity of newborn complications is related to the severity and duration of metabolic acidosis. As an example, a study of term infants who had umbilical cord artery blood pH at birth and within two hours after delivery found the incidence of newborn seizures was highest in the group of infants who had acidemia at birth that persisted through the first two hours of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In terms of fetal heart rate patterns, it has been estimated that fetal stress characterized by repetitive moderate or severe variable decelerations may increase the base deficit by 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    per 30 minutes; repetitive late or severe atypical variable decelerations (subacute fetal compromise) may increase the base deficit by 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    per 6 to 15 minutes; and terminal bradycardia (eg, from ruptured uterus, major abruption, or complete cord occlusion) may increase the base deficit by as much as 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    per two to three minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/44\">",
"     44",
"    </a>",
"    ]. By comparison, an uncomplicated labor results in a 3",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    change in base deficit over many hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/44\">",
"     44",
"    </a>",
"    ]. However, many factors affect the fetal response to hypoxia; these include an acute versus chronic process, presence of",
"    <span class=\"nowrap\">",
"     hypotension/hypoperfusion,",
"    </span>",
"    preterm versus term fetus, presence of anemia or functional cardiovascular anomalies.",
"   </p>",
"   <p>",
"    Meconium stained amniotic fluid (MSAF) complicates approximately 12 percent of pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/47\">",
"     47",
"    </a>",
"    ]. In a retrospective review of 766 cases of MSAF from 32 to 42 weeks of gestation, mean umbilical arterial pH did not vary with gestational age, indicating that acidemia is not increased in preterm gestations complicated by meconium passage before birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LIMITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal blood gas analysis has some limitations that should be considered when interpreting results. It should be remembered that a cord blood pH value alone does not distinguish between a primary fetal or placental disorder and the indirect effect of a maternal acid-base disorder. Considering maternal health status and each blood gas value can help define the primary pathologic process. Fetal blood gases also do not necessarily reflect asphyxial processes that occurred remote from delivery or are not global. lastly, comorbidities (eg, fetal growth restriction,anemia) and duration of insult are important biological modifiers of neurological and other end-organ risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical blood pH and blood gas analysis provides an objective method of assessing immediate newborn condition.",
"     </li>",
"     <li>",
"      Umbilical blood pH and gas analysis is especially useful in premature infants and term infants with low Apgar scores, severe growth restriction, meconium-stained amniotic fluid, or a nonreassuring fetal heart rate pattern during labor. It has also been suggested in cases of maternal thyroid disease, intrapartum fever, and multiple gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1\">",
"       1",
"      </a>",
"      ]. This test should be considered for all deliveries.",
"     </li>",
"     <li>",
"      Specimens should be collected in a syringe flushed with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and should be obtained from the umbilical artery of a doubly-clamped segment of umbilical cord. The cord should be clamped immediately after birth.",
"     </li>",
"     <li>",
"      Umbilical artery blood pH and gas values provide the best information regarding fetal acid-base status.",
"     </li>",
"     <li>",
"      Pathologic fetal acidemia is defined as an umbilical artery blood pH of less than 7.00. A pH less than 6.90 is even more predictive of neonatal morbidity. A base deficit greater than or equal to 12",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      suggests metabolic acidosis and is associated with an increased risk of neonatal morbidity.",
"     </li>",
"     <li>",
"      A low umbilical artery blood pH is probably the single most important criterion for defining hypoxia proximate to delivery that is severe enough to cause hypoxic ischemic encephalopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=see_link\">",
"       \"Etiology and pathogenesis of neonatal encephalopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A normal umbilical artery blood pH virtually excludes \"birth asphyxia.\"",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/1\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 348, November 2006: Umbilical cord blood gas and acid-base analysis. Obstet Gynecol 2006; 108:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/2\">",
"      Armstrong L, Stenson BJ. Use of umbilical cord blood gas analysis in the assessment of the newborn. Arch Dis Child Fetal Neonatal Ed 2007; 92:F430.",
"     </a>",
"    </li>",
"    <li>",
"     Nageotte, MP, Gilstrap, LC III. Intrapartum fetal surveillance. In: Creasy &amp; Resnik's Maternal-Fetal Medicine Principles and Practice, 6th ed, Creasy, Resnik, Iams, Lockwood, Moore (Eds), Saunders, Philadelphia, PA 2009. p.397.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/4\">",
"      Page FO, Martin JN, Palmer SM, et al. Correlation of neonatal acid-base status with Apgar scores and fetal heart rate tracings. Am J Obstet Gynecol 1986; 154:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/5\">",
"      Sykes GS, Molloy PM, Johnson P, et al. Do Apgar scores indicate asphyxia? Lancet 1982; 1:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/6\">",
"      Silverman F, Suidan J, Wasserman J, et al. The Apgar score: is it enough? Obstet Gynecol 1985; 66:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/7\">",
"      Low JA. The role of blood gas and acid-base assessment in the diagnosis of intrapartum fetal asphyxia. Am J Obstet Gynecol 1988; 159:1235.",
"     </a>",
"    </li>",
"    <li>",
"     Cunningham, FG, Leveno, KJ, Bloom, SL, et al. The newborn infant. In: Williams Obstetrics, 23rd ed, McGraw-Hill, New York, NY, 2010. p.590.",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynecologists, Royal College of Midwives: Towars safer childbirth. Minimum standards for the organization of labour wards. Report of joint working party. London: RCOG Press, 1999:22.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/10\">",
"      Armstrong L, Stenson B. Effect of delayed sampling on umbilical cord arterial and venous lactate and blood gases in clamped and unclamped vessels. Arch Dis Child Fetal Neonatal Ed 2006; 91:F342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/11\">",
"      Lievaart M, de Jong PA. Acid-base equilibrium in umbilical cord blood and time of cord clamping. Obstet Gynecol 1984; 63:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/12\">",
"      Wiberg N, K&auml;ll&eacute;n K, Olofsson P. Delayed umbilical cord clamping at birth has effects on arterial and venous blood gases and lactate concentrations. BJOG 2008; 115:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/13\">",
"      Beaulieu M, Lapointe Y, Vinet B. Stability of PO2, PCO2, and pH in fresh blood samples stored in a plastic syringe with low heparin in relation to various blood-gas and hematological parameters. Clin Biochem 1999; 32:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/14\">",
"      Duerbeck NB, Chaffin DG, Seeds JW. A practical approach to umbilical artery pH and blood gas determinations. Obstet Gynecol 1992; 79:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/15\">",
"      Sykes GS, Molloy PM. Effect of delays in collection or analysis on the results of umbilical cord blood measurements. Br J Obstet Gynaecol 1984; 91:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/16\">",
"      Hilger JS, Holzman IR, Brown DR. Sequential changes in placental blood gases and pH during the hour following delivery. J Reprod Med 1981; 26:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/17\">",
"      Strickland DM, Gilstrap LC 3rd, Hauth JC, Widmer K. Umbilical cord pH and PCO2: effect of interval from delivery to determination. Am J Obstet Gynecol 1984; 148:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/18\">",
"      Lynn A, Beeby P. Cord and placenta arterial gas analysis: the accuracy of delayed sampling. Arch Dis Child Fetal Neonatal Ed 2007; 92:F281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/19\">",
"      Riley RJ, Johnson JW. Collecting and analyzing cord blood gases. Clin Obstet Gynecol 1993; 36:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/20\">",
"      Nodwell A, Carmichael L, Ross M, Richardson B. Placental compared with umbilical cord blood to assess fetal blood gas and acid-base status. Obstet Gynecol 2005; 105:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/21\">",
"      Westgate J, Garibaldi JM, Greene KR. Umbilical cord blood gas analysis at delivery: a time for quality data. Br J Obstet Gynaecol 1994; 101:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/22\">",
"      Blechner JN. Maternal-fetal acid-base physiology. Clin Obstet Gynecol 1993; 36:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/23\">",
"      Malin GL, Morris RK, Khan KS. Strength of association between umbilical cord pH and perinatal and long term outcomes: systematic review and meta-analysis. BMJ 2010; 340:c1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/24\">",
"      Ramin SM, Gilstrap LC 3rd, Leveno KJ, et al. Umbilical artery acid-base status in the preterm infant. Obstet Gynecol 1989; 74:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/25\">",
"      Dickinson JE, Eriksen NL, Meyer BA, Parisi VM. The effect of preterm birth on umbilical cord blood gases. Obstet Gynecol 1992; 79:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/26\">",
"      Dildy GA. Fetal pulse oximetry. Clin Obstet Gynecol 2011; 54:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/27\">",
"      Bloom SL, Spong CY, Thom E, et al. Fetal pulse oximetry and cesarean delivery. N Engl J Med 2006; 355:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/28\">",
"      Yeomans ER, Hauth JC, Gilstrap LC 3rd, Strickland DM. Umbilical cord pH, PCO2, and bicarbonate following uncomplicated term vaginal deliveries. Am J Obstet Gynecol 1985; 151:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/29\">",
"      Victory R, Penava D, Da Silva O, et al. Umbilical cord pH and base excess values in relation to adverse outcome events for infants delivering at term. Am J Obstet Gynecol 2004; 191:2021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/30\">",
"      Gregg AR, Weiner CP. \"Normal\" umbilical arterial and venous acid-base and blood gas values. Clin Obstet Gynecol 1993; 36:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/31\">",
"      Gilstrap LC 3rd, Leveno KJ, Burris J, et al. Diagnosis of birth asphyxia on the basis of fetal pH, Apgar score, and newborn cerebral dysfunction. Am J Obstet Gynecol 1989; 161:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/32\">",
"      Goldaber KG, Gilstrap LC 3rd. Correlations between obstetric clinical events and umbilical cord blood acid-base and blood gas values. Clin Obstet Gynecol 1993; 36:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/33\">",
"      King TA, Jackson GL, Josey AS, et al. The effect of profound umbilical artery acidemia in term neonates admitted to a newborn nursery. J Pediatr 1998; 132:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/34\">",
"      Sehdev HM, Stamilio DM, Macones GA, et al. Predictive factors for neonatal morbidity in neonates with an umbilical arterial cord pH less than 7.00. Am J Obstet Gynecol 1997; 177:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/35\">",
"      Winkler CL, Hauth JC, Tucker JM, et al. Neonatal complications at term as related to the degree of umbilical artery acidemia. Am J Obstet Gynecol 1991; 164:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/36\">",
"      Goldaber KG, Gilstrap LC 3rd, Leveno KJ, et al. Pathologic fetal acidemia. Obstet Gynecol 1991; 78:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/37\">",
"      Graham EM, Ruis KA, Hartman AL, et al. A systematic review of the role of intrapartum hypoxia-ischemia in the causation of neonatal encephalopathy. Am J Obstet Gynecol 2008; 199:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/38\">",
"      Hafstrom M, Ehnberg S, Blad S, et al. Developmental Outcome at 6.5 Years After Acidosis in Term Newborns: A Population-Based Study. Pediatrics 2012; 129:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/39\">",
"      Andres RL, Saade G, Gilstrap LC, et al. Association between umbilical blood gas parameters and neonatal morbidity and death in neonates with pathologic fetal acidemia. Am J Obstet Gynecol 1999; 181:867.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics, American College of Obstetricians and Gynecologists. Neonatal encephalopathy and cerebral palsy: defining the pathogenesis and pathophysiology. Elk Grove Village (IL): AAP; Washington, DC: ACOG; 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/41\">",
"      Low JA, Panagiotopoulos C, Derrick EJ. Newborn complications after intrapartum asphyxia with metabolic acidosis in the term fetus. Am J Obstet Gynecol 1994; 170:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/42\">",
"      Low JA. Intrapartum fetal asphyxia: definition, diagnosis, and classification. Am J Obstet Gynecol 1997; 176:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/43\">",
"      Low JA, Lindsay BG, Derrick EJ. Threshold of metabolic acidosis associated with newborn complications. Am J Obstet Gynecol 1997; 177:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/44\">",
"      Ross MG, Gala R. Use of umbilical artery base excess: algorithm for the timing of hypoxic injury. Am J Obstet Gynecol 2002; 187:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/45\">",
"      Cohen Y, Nimord A, Ascher-Landsberg J, et al. Reference values for strong ion difference--a novel tool for fetal metabolic assessment. Eur J Obstet Gynecol Reprod Biol 2009; 145:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/46\">",
"      Casey BM, Goldaber KG, McIntire DD, Leveno KJ. Outcomes among term infants when two-hour postnatal pH is compared with pH at delivery. Am J Obstet Gynecol 2001; 184:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35702/abstract/47\">",
"      Oyelese Y, Culin A, Ananth CV, et al. Meconium-stained amniotic fluid across gestation and neonatal acid-base status. Obstet Gynecol 2006; 108:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5400 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-F42F8ABDFE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35702=[""].join("\n");
var outline_f34_55_35702=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preterm infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Term infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGIC FETAL ACIDEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Base deficit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LIMITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/23/379\" title=\"table 1\">",
"      Preterm umbilical cord gases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/19/315\" title=\"table 2\">",
"      Umbilical cord gases at term",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/61/9173?source=related_link\">",
"      Chapter 10A: Acids and bases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30953?source=related_link\">",
"      Etiology and pathogenesis of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1253?source=related_link\">",
"      Fetal acid-base physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_55_35703="HIV-associated eosinophilic folliculitis";
var content_f34_55_35703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87125%7EDERM%2F54404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87125%7EDERM%2F54404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    HIV-associated eosinophilic folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules and excoriated papules are present on the back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HIV-associated eosinophilic folliculitis is characterized by recurrent, pruritic crops of discrete, erythematous, urticarial follicular papules and rare pustules, with a diameter of 3 to 5 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Toby Maurer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35703=[""].join("\n");
var outline_f34_55_35703=null;
var title_f34_55_35704="Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children";
var content_f34_55_35704=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35704/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35704/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35704/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35704/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35704/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35704/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35704/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/55/35704/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemolytic uremic syndrome (HUS) is defined by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/1\">",
"     1",
"    </a>",
"    ]. It is one of the main causes of acute renal injury in children under the age of three years.",
"   </p>",
"   <p>",
"    This disorder is divided by whether or not there is an association with bacteria that produce a Shiga toxin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shiga toxin associated HUS &ndash; Shiga toxin (Stx) associated HUS is the most common form of HUS in children accounting for 90 percent of all cases. It usually occurs after a prodromal episode of diarrhea that is frequently bloody. In the majority of cases, typical HUS is associated with strains of Escherichia coli that produce a Shiga toxin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/3-6\">",
"       3-6",
"      </a>",
"      ]. This form is also referred to as typical, classical, or diarrhea-associated HUS, D+ HUS, or Shiga toxin-associated HUS.",
"      <br/>",
"      <br/>",
"      Cases of HUS in children due to Shiga toxin-producing Escherichia coli (E. coli) infections other than colitis (eg, urinary tract infections) can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Although these cases are not associated with diarrhea, the clinical course and pathophysiology are the same as the D+ HUS and will be included in the discussion on Stx HUS. In addition, D+ HUS associated with Shigella dysenteriae serotype 1 will be included in the discussion of Stx HUS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Non-Shiga toxin associated HUS &ndash; Non-Shiga toxin (NStx) associated HUS is a heterogeneous group of disorders distinguished clinically by the absence of diarrhea or Shiga toxin-producing E. coli infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. This disorder is also referred to as atypical, nondiarrhea-associated HUS, D- HUS, or sporadic HUS. Complement disorders involving factors H, I, and membrane cofactor protein and Streptococcus pneumoniae infection have been associated with cases of NStx HUS. The clinical manifestations, diagnosis, treatment, and prognosis of NStx HUS are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link\">",
"       \"Atypical hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of Stx HUS in children are presented in this topic review. The treatment and prognosis of this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stx HUS is also a different disorder from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) in adults. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shiga toxin (Stx) hemolytic uremic syndrome (HUS) occurs after an infection with Shiga toxin-producing enterohemorrhagic E. coli (EHEC) or Shigella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/9,13-15\">",
"     9,13-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608346\">",
"    <span class=\"h2\">",
"     Enterohemorrhagic E. coli",
"    </span>",
"    &nbsp;&mdash;&nbsp;EHEC is the most common cause of Stx HUS, accounting for over 70 percent of cases of postdiarrheal HUS in the United States. Different strains of EHEC have been associated with both sporadic and epidemic Stx HUS cases throughout the world.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, most cases of Stx HUS are caused by E. coli 0157:H7 and typically occur in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In May 2011, a previously unknown EHEC strain, E. coli O104:H4, was identified as the cause of Stx HUS in a large outbreak in Germany [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/18-20\">",
"       18-20",
"      </a>",
"      ]. This new strain appeared to be particularly virulent, as 30 percent of infected patients with E. coli O104:H4 developed HUS. Unlike cases due to E. coli 0157 that primarily affect children, more than 80 percent of HUS cases occurred in adults. In addition, two-thirds of the patients were women. The clinical features and course, and outcome in children who developed HUS caused by E. coli 0104:H4 were similar to that observed in patients with HUS due to other strains of EHEC with two exceptions: most patients with E. coli 0104:H4 associated disease were older than 10 years of age and were from families with a high socioeconomic status [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Australia, about one-half of cases of postdiarrheal HUS are due to E. coli 0111 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In an outbreak in the United States, HUS developed in 26 of 156 patients with confirmed or probable E coli 0111 infections in August 2008 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/25\">",
"       25",
"      </a>",
"      ]. Unlike epidemics with E. coli 0157, 60 percent of HUS cases occurred in adults. Two-thirds of patient required dialysis, and one patient died.",
"     </li>",
"     <li>",
"      In Italy, the primary strain has been E. coli 026 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The microbiology and diagnoses of EHEC infections are discussed separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=see_link\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608504\">",
"    <span class=\"h2\">",
"     Shigella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shigella dysenteriae type 1 associated HUS occurs in India, Bangladesh, and southern Africa. Although the pathogenesis of disease is similar to that of HUS induced by O157 E. coli infection, the disease is usually more severe with an acute mortality rate of 15 percent and over 40 percent of patients develop chronic renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38535?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Hemolytic-uremic syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shiga toxin (Stx) hemolytic uremic syndrome (HUS) accounts for over 90 percent of cases of HUS in children. It principally affects children under the age of five years. The annual incidence of the disease in North America and Western Europe is about 2 to 3 per 100,000 children less than five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study from a voluntary surveillance system of 31 French pediatric nephrology units reported an incidence of 0.7 cases per 100,000 children less than 15 years and a higher incidence of 2 per 100,000 children less than five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/29\">",
"     29",
"    </a>",
"    ]. In two-thirds of the cases, Stx infection was confirmed and E Coli 0157 was the causative agent in most of these cases. A case-control prospective study from the same French surveillance system showed that consumption of undercooked ground beef and contact with a person with diarrhea were the major risk factors for sporadic cases of HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although found in other animals, cattle are the main vectors of E. coli O157:H7, with the bacteria being present in the cattle intestine and feces. Infection in humans occurs following ingestion of contaminated undercooked meat, unpasteurized milk or milk products, water, fruits or vegetables [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/30\">",
"     30",
"    </a>",
"    ]. Secondary human-to-human contamination is also possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Thus, transmission from child to child in day-care centers is a concern. ST-associated HUS also occurs in siblings a few days or weeks apart due to the same contamination or due to human to human transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, there is a case report of neonatal HUS due to maternal transmission from a healthy mother who was asymptomatic carrier of a Shiga toxin-producing E. coli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stx HUS occurs most commonly in the summer months and is more frequent in rural versus urban populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/14\">",
"     14",
"    </a>",
"    ]. Most cases are sporadic, but outbreaks are often reported due to a common contaminated food or water source.",
"   </p>",
"   <p>",
"    A more detailed discussion on the epidemiology of E. coli O157:H7 is found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=see_link&amp;anchor=H4450891#H4450891\">",
"     \"Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Shiga toxin (Stx) hemolytic uremic syndrome (HUS) have a prodromal illness with abdominal pain, vomiting, and diarrhea that generally precedes the development of HUS by 5 to 10 days (",
"    <a class=\"graphic graphic_figure graphicRef75352 \" href=\"mobipreview.htm?28/53/29534\">",
"     figure 1",
"    </a>",
"    ). The diarrhea and associated gastrointestinal complaints may mimic those of ulcerative colitis, other enteric infections, and appendicitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32826?source=see_link\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HUS complicates 6 to 9 percent of enterohemorrhagic E. coli infections and usually begins five to ten days after the onset of diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/27,28,32\">",
"     27,28,32",
"    </a>",
"    ]. HUS is defined by the sudden onset of the following triad (",
"    <a class=\"graphic graphic_figure graphicRef75352 \" href=\"mobipreview.htm?28/53/29534\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemolytic anemia with fragmented erythrocytes",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Acute renal injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial clinical and laboratory manifestations and mortality of patients with Stx HUS were well described in the largest prospective multicenter study of pediatric HUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/6\">",
"     6",
"    </a>",
"    ]. This German and Austrian report included 394 children (mean age of three years) with HUS, of whom 91 percent had an episode of prodromal diarrhea (which was bloody in 57 percent); HUS was defined as acute microangiopathic hemolytic anemia (hemoglobin level less than 10",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    thrombocytopenia (less than 150 x 10(9)",
"    <span class=\"nowrap\">",
"     platelets/L),",
"    </span>",
"    and acute renal injury. The following findings were found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nearly one-half of cases occurred from June to September, with evidence of pathogenic E. coli infection being reported in 83 percent.",
"     </li>",
"     <li>",
"      Mean minimum hemoglobin and platelet values were 6.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (range 5.3 to 6.9",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      and 37 x 10(9)",
"      <span class=\"nowrap\">",
"       cells/L",
"      </span>",
"      (range 25 to 55 x 10(9)",
"      <span class=\"nowrap\">",
"       cells/L),",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Dialysis was required in 61 percent of patients, with anuria occurring in 40 percent. Dialysis was provided for a mean period of 10 days.",
"     </li>",
"     <li>",
"      Neurologic symptoms, principally seizures and somnolence, were observed in 25 percent.",
"     </li>",
"     <li>",
"      The mortality rate was 4 percent, all deaths occurred in patients with a diarrheal prodrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections provide an overview concerning the clinical and laboratory manifestations of Stx HUS as reported in multiple studies from different geographic locations over several decades.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microangiopathic hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The microangiopathic hemolytic anemia is characterized by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin levels usually less than 8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Negative Coombs' tests",
"     </li>",
"     <li>",
"      Peripheral blood smear with a large number of schistocytes (up to 10 percent of red cells) and helmet cells (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"mobipreview.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef50715 \" href=\"mobipreview.htm?22/13/22739\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional findings of hemolysis include elevation of the serum indirect bilirubin concentration and reduction in the serum haptoglobin concentration. The serum lactate dehydrogenase (LDH) level is typically very high. Although hemolysis may recur over a several-week period, there is no correlation between the severity of anemia and the severity of renal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is characterized by a platelet count below",
"    <span class=\"nowrap\">",
"     140,000/mm3",
"    </span>",
"    and usually about",
"    <span class=\"nowrap\">",
"     40,000/mm3.",
"    </span>",
"    Despite this, there is usually no purpura or active bleeding. The degree of thrombocytopenia is unrelated to the severity of renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Acute renal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of renal involvement ranges from hematuria and proteinuria to severe renal failure and oligoanuria. Severe renal failure occurs in one-half of cases. Hypertension is common, particularly after the administration of excess fluids or blood transfusions. Most patients have microscopic hematuria on urinalysis, although macroscopic hematuria may be observed. Red blood cell casts are occasionally seen, but are not a typical feature.",
"   </p>",
"   <p>",
"    Although as many as 50 percent of those with HUS require dialysis during the acute phase, the prognosis for recovery of renal function is generally favorable (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Prognosis'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Acute renal failure in children is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=see_link\">",
"     \"Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;HUS commonly affects other organ systems, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system &ndash; Manifestations of central nervous system (CNS) involvement, which are seen in up to 20 percent of children with Stx HUS, include seizures, coma, stroke, hemiparesis, and cortical blindness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/34\">",
"       34",
"      </a>",
"      ]. In patients with severe neurologic findings, brain magnetic resonance imaging reveals bilateral hypersignal on T2-weighted and hyposignal on T1-weighted images in the basal ganglia, thalami, and brainstem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/35\">",
"       35",
"      </a>",
"      ]. Severe CNS involvement is associated with increased mortality.",
"     </li>",
"     <li>",
"      Gastrointestinal tract &ndash; Any area from the esophagus to the perianal area can be involved. The more serious manifestations include severe hemorrhagic colitis, bowel necrosis and perforation, rectal prolapse, peritonitis, and intussusception [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac dysfunction &ndash; Cardiac dysfunction can be due to cardiac ischemia detected by elevated levels of troponin 1 and fluid overload.",
"     </li>",
"     <li>",
"      Pancreas &ndash; During the acute phase, less than 10 percent of patients develop glucose intolerance. Transient diabetes mellitus may occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/36\">",
"       36",
"      </a>",
"      ], and rarely permanent diabetes mellitus, which may develop years later.",
"     </li>",
"     <li>",
"      Liver &ndash; Hepatomegaly",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased serum transaminases are frequent findings.",
"     </li>",
"     <li>",
"      Hematology &ndash; In addition to anemia and thrombocytopenia, leukocytosis is common in diarrhea-induced HUS; the prognosis is worse with increased white blood cell counts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evidence of E. coli infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although laboratory diagnosis of Enterohemorrhagic E. coli (EHEC) infection can be made by stool culture, including",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    MacConkey medium, the bacteria are only present in the stools for a few days and, even if present, may not be detected by culture from stool samples. The results of conventional stool culture and analysis have been described earlier. New diagnostic tools for pathogenic E. coli infection directly detect Shiga toxin genes by polymerase chain reaction (PCR) in fecal isolates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H2\">",
"     'Microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As Shiga-toxin genes are only present in stools for a few days, enterohemorrhagic E. coli infection may be confirmed by the detection of IgM antibodies directed against the VETC lipopolysaccharide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/39\">",
"     39",
"    </a>",
"    ]. In one study of 66 children with culture-proven E. coli 0157:H7 infection and 132 controls, IgM antibodies had a 95 and 99 percent sensitivity and specificity, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/39\">",
"     39",
"    </a>",
"    ]. However, the accuracy of these findings in patients with similar clinical symptoms but without positive cultures for E. coli 0157:H7 is unclear. Further study is required to clarify their clinical role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologically, Shiga toxin (Stx) hemolytic uremic syndrome (HUS) is associated with glomerular thrombotic microangiopathy (TMA), which can extend to the afferent arteriole. Three types of involvement of the renal parenchyma are observed (",
"    <a class=\"graphic graphic_picture graphicRef63511 graphicRef54840 graphicRef69687 graphicRef78330 graphicRef75317 \" href=\"mobipreview.htm?43/7/44154\">",
"     picture 3A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A glomerular thrombotic microangiopathy, characterized by a thickening of the capillary walls, with a double-contour appearance due to a widening of the subendothelial space. Endothelial cells are swollen and may obstruct the capillary lumen. The lesions affect the preglomerular arterioles and the glomerular capillaries, and the mesangial matrix has a fibrillar appearance. The glomeruli are enlarged and the capillaries may contain red cells and platelets. Lesions of glomerular thrombotic microangiopathy affect a variable proportion of the glomeruli.",
"     </li>",
"     <li>",
"      Cortical necrosis may be patchy or, more rarely, diffuse and affect the entire superficial cortex. These lesions are observed in the more severe cases of Stx HUS with prolonged anuria, and they carry a high risk of chronic renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although more often observed with NStx (atypical) HUS, a pattern of predominant arterial thrombotic microangiopathy can be observed with Stx HUS. In this pattern of arterial TMA, which is unusual in children with Stx HUS, arterioles and interlobular arteries are severely affected with intimal edema, necrosis of the arteriolar wall, luminal narrowing, and thrombosis. Glomeruli appear ischemic and shrunken, with splitting of the capillary wall and wrinkling of the glomerular basement membrane. This lesion is responsible for severe hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A patient with a recent history of diarrhea (possibly bloody) who presents with symptoms and signs of a multisystem disorder requires a quick and accurate assessment for the possible development of hemolytic uremic syndrome (HUS). As an example, decreasing urine volume in an adequately hydrated child with diarrhea should prompt the consideration of new-onset renal injury, particularly due to HUS.",
"   </p>",
"   <p>",
"    The diagnosis of Shiga toxin (Stx) HUS in children is generally made on clinical grounds from the characteristic clinical and laboratory findings previously described: a prodrome of diarrhea, followed by abrupt onset of the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury.",
"   </p>",
"   <p>",
"    Although laboratory diagnosis of enterohemorrhagic E. coli infection can be made by stool culture, the bacteria are only present in the stools for a few days and, even if present, may not be detected by culture from stool samples. Other evidence of E. coli infection include detection of Shiga-toxin genes in stools by polymerase chain reaction (PCR) or serum IgM antibodies against lipopolysaccharide of major enterohemorrhagic E. coli (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Evidence of E. coli infection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=see_link\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the diagnosis of Stx HUS in children should not be based upon the results of microbial culture, although positive results are supportive of the diagnosis. In most patients, treatment is initiated because of the clinical diagnosis of HUS based on the triad of hemolytic anemia with fragmented red blood cells, thrombocytopenia, and acute renal injury. Renal biopsy, which is rarely performed, may be helpful in selected patients in whom the diagnosis is uncertain and thrombocytopenia is not limiting.",
"   </p>",
"   <p>",
"    The characteristic prodrome of diarrhea is absent in some affected children. In this setting, the presence of the defining triad in an age appropriate child should prompt consideration of infection of other organs, particularly the urinary tract, with a Shiga toxin-producing organism. The diagnosis may be confirmed with serologic testing or a positive microbial culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The constellation of clinical and laboratory findings of hemolytic uremic syndrome (HUS) in children can be mimicked by several disorders such as the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe abdominal pain, frankly bloody diarrhea, fever, and leukocytosis occur in other enteric infections (such as Salmonella, Campylobacter, Yersinia, amebiasis, and Clostridium difficile), and with Henoch-Sch&ouml;nlein purpura. With severe diarrhea, elevations in the serum creatinine concentration and BUN are typically due to volume depletion, not intrinsic renal disease. Thus, the combination of severe diarrhea and renal insufficiency due to volume depletion may be confused with that due to HUS. This constellation of findings in the absence of thrombocytopenia and hemolytic anemia distinguishes these enteric infections from HUS. The rash and arthralgias of Henoch-Sch&ouml;nlein purpura (IgA vasculitis) also help to differentiate it from HUS,",
"     </li>",
"     <li>",
"      The combination of thrombocytopenia, hemolytic anemia, and renal injury can also occur in systemic vasculitis, sepsis, and disseminated intravascular coagulation (DIC). Patients with vasculitis typically have other systemic symptoms (such as arthralgias and rash), a normal platelet count. In addition, the characteristic neurologic involvement in patients with vasculitis is peripheral (eg, mononeuritis multiplex) rather than central.",
"      <br/>",
"      <br/>",
"      The distinction between HUS and DIC is more difficult, and is based upon the history and laboratory studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/43\">",
"       43",
"      </a>",
"      ]. DIC is associated with intravascular activation of the coagulation cascade, leading to intravascular deposition of fibrin thrombi, the consumption of all of the components of this cascade, and microangiopathic hemolytic anemia. As a result, patients with DIC typically have thrombocytopenia, low circulating levels of fibrinogen and factors V and VIII, and prolongation of the prothrombin and partial thromboplastin times (PT and aPTT, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link\">",
"       \"Disseminated intravascular coagulation in infants and children\"",
"      </a>",
"      .) In comparison, patients with Shiga toxin (Stx) HUS have isolated platelet consumption due to endothelial injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35704/abstract/44\">",
"       44",
"      </a>",
"      ]. The net effect is thrombocytopenia; increased turnover of platelets, but not fibrin; and usually normal levels of the coagulation components, and little or no prolongation of the PT or aPTT.",
"     </li>",
"     <li>",
"      NStx HUS is defined by the characteristic triad of HUS (microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury), but without a diarrheal prodrome. As previously mentioned, some cases of Shiga toxin associated HUS may not present with colitis and diarrhea. Unlike Stx disease, NStx HUS is more likely to recur, have a severe clinical course (particularly renal insufficiency and hypertension), and be associated with a positive family history. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=see_link\">",
"       \"Atypical hemolytic uremic syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemolytic-uremic syndrome (HUS) is characterized by the simultaneous occurrence of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury. This disorder is divided into Shiga toxin (Stx) associated HUS (also referred to as typical HUS) and non-Shiga toxin (NStx) associated HUS (also referred to as atypical HUS) based upon clinical presentation and the association with bacteria that produce Shiga toxin.",
"   </p>",
"   <p>",
"    Stx HUS primarily occurs after a prodromal episode of diarrhea that is frequently bloody. Stx HUS is also referred to as typical, diarrhea-associated HUS (D+ HUS) or Shiga toxin-associated HUS. It principally affects children under the age of five years.",
"   </p>",
"   <p>",
"    Non-Shiga toxin associated (NStx) HUS is a heterogeneous disorder distinguished clinically by the absence of diarrhea or Shiga toxin-producing E. coli infection, but with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stx HUS primarily follows an infection with Shiga toxin producing strains of Escherichia coli. The most common serotype in the United States is O157:H7, which is found in 70 percent of cases, but other serotypes have been reported. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stx HUS represents 90 percent of cases of HUS observed in children. The annual incidence of the disease in North America and Western Europe is 2 to 3 per 100,000 children less than five years of age. This disorder is commonly observed during the summer and is more frequently seen in rural versus urban populations. Most cases of typical HUS are sporadic, but outbreaks have been reported. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with Stx HUS have a prodromal illness with abdominal pain, vomiting, and diarrhea that immediately precedes the development of HUS (",
"    <a class=\"graphic graphic_figure graphicRef75352 \" href=\"mobipreview.htm?28/53/29534\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    HUS is defined by the sudden onset of the",
"    <strong>",
"     triad",
"    </strong>",
"    of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia &ndash; Hemoglobin levels are usually less than 8",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      The Coomb's test is negative and the peripheral blood smear is characterized by the large number of schistocytes and helmet cells. There is no correlation between the severity of the anemia and the severity of the renal disease.",
"     </li>",
"     <li>",
"      Thrombocytopenia &ndash; Platelet counts are generally around",
"      <span class=\"nowrap\">",
"       40,000/mm3.",
"      </span>",
"      There is no correlation between the degree of thrombocytopenia and the severity of the renal disease.",
"     </li>",
"     <li>",
"      Acute renal injury &ndash; The severity of renal involvement ranges from hematuria and proteinuria to severe renal failure and oligoanuria, which occur in one-half of cases. Hypertension is also frequently observed. Although as many as 50 percent of those with HUS require dialysis during the acute phase, the prognosis for recovery of renal function is generally favorable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stx HUS may affect several other organ systems including the central nervous system (CNS), gastrointestinal tract, pancreas, and liver. Severe CNS involvement (eg, seizures, coma, and stroke) is associated with significant mortality. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical and laboratory manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of Stx HUS in children is generally made on clinical grounds from the characteristic clinical and laboratory findings of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal injury following a diarrheal prodrome, usually due to enterohemorrhagic E. coli. The demonstration of Shiga-toxin exposure relies on one of the following: positive stool culture, detection of Shiga-toxin genes in stools by polymerase chain reaction (PCR), and the presence of serum IgM antibodies against lipopolysaccharide of major enterohemorrhagic E. coli. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The constellation of clinical and laboratory findings of HUS in children can be mimicked in certain other disorders. These include other enteric infections, Henoch-Sch&ouml;nlein purpura, systemic vasculitis, sepsis, and disseminated intravascular coagulation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/1\">",
"      Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/2\">",
"      Boyer O, Niaudet P. Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol 2011; 2011:908407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/3\">",
"      Repetto HA. Epidemic hemolytic-uremic syndrome in children. Kidney Int 1997; 52:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/4\">",
"      Yukioka H, Kurita S. Escherichia coli O157 infection disaster in Japan, 1996. Eur J Emerg Med 1997; 4:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/5\">",
"      Slutsker L, Ries AA, Greene KD, et al. Escherichia coli O157:H7 diarrhea in the United States: clinical and epidemiologic features. Ann Intern Med 1997; 126:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/6\">",
"      Gerber A, Karch H, Allerberger F, et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/7\">",
"      Starr M, Bennett-Wood V, Bigham AK, et al. Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review. Clin Infect Dis 1998; 27:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/8\">",
"      Hogan MC, Gloor JM, Uhl JR, et al. Two cases of non-O157:H7 Escherichia coli hemolytic uremic syndrome caused by urinary tract infection. Am J Kidney Dis 2001; 38:E22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/9\">",
"      Houdouin V, Doit C, Mariani P, et al. A pediatric cluster of Shigella dysenteriae serotype 1 diarrhea with hemolytic uremic syndrome in 2 families from France. Clin Infect Dis 2004; 38:e96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/10\">",
"      Bhimma R, Rollins NC, Coovadia HM, Adhikari M. Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatr Nephrol 1997; 11:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/11\">",
"      Constantinescu AR, Bitzan M, Weiss LS, et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004; 43:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/12\">",
"      Neuhaus TJ, Calonder S, Leumann EP. Heterogeneity of atypical haemolytic uraemic syndromes. Arch Dis Child 1997; 76:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/13\">",
"      Fitzpatrick M. Haemolytic uraemic syndrome and E coli O157. BMJ 1999; 318:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/14\">",
"      Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/15\">",
"      van de Kar NC, Roelofs HG, Muytjens HL, et al. Verocytotoxin-producing Escherichia coli infection in hemolytic uremic syndrome in part of western Europe. Eur J Pediatr 1996; 155:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/16\">",
"      Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/17\">",
"      Mody RK, Luna-Gierke RE, Jones TF, et al. Infections in pediatric postdiarrheal hemolytic uremic syndrome: factors associated with identifying shiga toxin-producing Escherichia coli. Arch Pediatr Adolesc Med 2012; 166:902.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.rki.de/EN/Home/homepage__node.html (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     file://www.cdc.gov/media/releases/2011/s0601_ecoligermany.html?s_cid=2011_s0601_ecoligermany (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     file://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19878 (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/21\">",
"      Kemper MJ. Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol 2012; 27:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/22\">",
"      Loos S, Ahlenstiel T, Kranz B, et al. An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012; 55:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Community outbreak of hemolytic uremic syndrome attributable to Escherichia coli O111:NM--South Australia 1995. MMWR Morb Mortal Wkly Rep 1995; 44:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/24\">",
"      Elliott EJ, Robins-Browne RM, O'Loughlin EV, et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001; 85:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/25\">",
"      Piercefield EW, Bradley KK, Coffman RL, Mallonee SM. Hemolytic Uremic Syndrome After an Escherichia coli O111 Outbreak. Arch Intern Med 2010; 170:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/26\">",
"      Tozzi AE, Caprioli A, Minelli F, et al. Shiga toxin-producing Escherichia coli infections associated with hemolytic uremic syndrome, Italy, 1988-2000. Emerg Infect Dis 2003; 9:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/27\">",
"      Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157:H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/28\">",
"      Bell BP, Goldoft M, Griffin PM, et al. A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA 1994; 272:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/29\">",
"      Espi&eacute; E, Grimont F, Mariani-Kurkdjian P, et al. Surveillance of hemolytic uremic syndrome in children less than 15 years of age, a system to monitor O157 and non-O157 Shiga toxin-producing Escherichia coli infections in France, 1996-2006. Pediatr Infect Dis J 2008; 27:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/30\">",
"      Vaillant V, Espi&eacute; E, de Valk H, et al. Undercooked ground beef and person-to-person transmission as major risk factors for sporadic hemolytic uremic syndrome related to Shiga-toxin producing Escherchia coli infections in children in France. Pediatr Infect Dis J 2009; 28:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/31\">",
"      Stritt A, Tschumi S, Kottanattu L, et al. Neonatal hemolytic uremic syndrome after mother-to-child transmission of a low-pathogenic stx2b harboring shiga toxin-producing Escherichia coli. Clin Infect Dis 2013; 56:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/32\">",
"      Su C, Brandt LJ. Escherichia coli O157:H7 infection in humans. Ann Intern Med 1995; 123:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/33\">",
"      Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994; 125:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/34\">",
"      Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2010; 5:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/35\">",
"      Jeong YK, Kim IO, Kim WS, et al. Hemolytic uremic syndrome: MR findings of CNS complications. Pediatr Radiol 1994; 24:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/36\">",
"      de Buys Roessingh AS, de Lagausie P, Baudoin V, et al. Gastrointestinal complications of post-diarrheal hemolytic uremic syndrome. Eur J Pediatr Surg 2007; 17:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/37\">",
"      Rahman RC, Cobe&ntilde;as CJ, Drut R, et al. Hemorrhagic colitis in postdiarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol 2012; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/38\">",
"      Siegler RL, Pavia AT, Christofferson RD, Milligan MK. A 20-year population-based study of postdiarrheal hemolytic uremic syndrome in Utah. Pediatrics 1994; 94:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/39\">",
"      Ludwig K, Bitzan M, Bobrowski C, M&uuml;ller-Wiefel DE. Escherichia coli O157 fails to induce a long-lasting lipopolysaccharide-specific, measurable humoral immune response in children with hemolytic-uremic syndrome. J Infect Dis 2002; 186:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/40\">",
"      Habib R, Levy M, Gagnadoux M, et al. Prognosis of the hemolytic uremic syndrome in children. Adv Nephrol Necker Hosp 1982; 11:99.",
"     </a>",
"    </li>",
"    <li>",
"     Habib R. Pathology of the hemolytic and uremic syndrome. In: Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura, Kaplan BS, Trompeter R, Moake J (Eds), Dekker, New York 1992. p.315.",
"    </li>",
"    <li>",
"     Loirat C, Taylor CM. Hemolytic Uremic Syndromes. In: Pediatric Nephrology, 4th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott, Williams &amp; Wilkins, Baltimore 2004. p.887.",
"    </li>",
"    <li>",
"     Marder VJ, Martin SE, Francis CW, Colman RW. Consumptive thrombo-hemorrhagic disorders. In: emostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd ed, Colman RW, Hirsh J, Marder VJ, Salzman EW (Eds), Lippincott, Philadelphia 1987. p.975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35704/abstract/44\">",
"      Neame PB, Hirsh J, Browman G, et al. Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J 1976; 114:1108.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6081 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-218.7.204.202-34378B5ED4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35704=[""].join("\n");
var outline_f34_55_35704=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608346\">",
"      Enterohemorrhagic E. coli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H608504\">",
"      Shigella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL AND LABORATORY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microangiopathic hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute renal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other organ involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evidence of E. coli infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6081\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6081|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/53/29534\" title=\"figure 1\">",
"      Timeline course HUS in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6081|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/13/22739\" title=\"picture 2\">",
"      Helmet cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/51/22329\" title=\"picture 3A\">",
"      HUS Glomerular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/61/12246\" title=\"picture 3B\">",
"      HUS Vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26389\" title=\"picture 3C\">",
"      HUS Vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/19/34099\" title=\"picture 3D\">",
"      HUS vascular III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/3/8255\" title=\"picture 3E\">",
"      HUS IF IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/53/19290?source=related_link\">",
"      Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/52/43849?source=related_link\">",
"      Atypical hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/19/18745?source=related_link\">",
"      Microbiology, pathogenesis, epidemiology, and prevention of enterohemorrhagic Escherichia coli (EHEC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_55_35705="Causes of neutrophilia";
var content_f34_55_35705=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of neutrophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35705/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35705/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35705/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35705/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35705/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/55/35705/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/55/35705/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/55/35705/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal total white blood cell (WBC) count in adults varies from 4400 to 11,000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (4.4 to 11.0 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L),",
"    </span>",
"    the majority of which (approximately 60 percent) are mature neutrophils.",
"   </p>",
"   <p>",
"    Leukocytosis is defined as a total WBC more than two standard deviations above the mean, or a value of greater than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    in adults. Since the limits of normal include two standard deviations above the mean, 2.5 percent of the normal population will have a total WBC count above this value. This becomes important when an otherwise normal patient with a modest increase in WBC count is being evaluated. Such patients may be included with those considered to have chronic idiopathic neutrophilia (see below).",
"   </p>",
"   <p>",
"    Neutrophilia, the major subject of this topic review, is defined as an increase in the absolute neutrophil count. It is most often seen in the setting of an increased total white blood cell count (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The major causes of neutrophilia will be reviewed here. The mechanisms of neutrophilia and the approach to the patient with this condition are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31303?source=see_link\">",
"     \"Definition and mechanisms of leukocytosis and neutrophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link\">",
"     \"Approach to the patient with neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated above, leukocytosis is defined as a total white blood cell count more than two standard deviations above the mean, or a value of greater than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    in adults. While leukocytosis is most commonly due to an increase in the absolute number of mature neutrophils (neutrophilia), it can, on occasion, reflect a marked increase in the absolute numbers of lymphocytes, eosinophils, monocytes, or, more rarely, basophils.",
"   </p>",
"   <p>",
"    By convention, leukocytosis to values in excess of 50,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    when due to causes other than leukemia, is termed a leukemoid reaction. Infection and the administration of hematopoietic growth factors or all-trans retinoic acid are the major causes of a leukemoid reaction.",
"   </p>",
"   <p>",
"    Neutrophilic leukocytosis is defined as a total WBC greater than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    plus an absolute neutrophil count (ANC) more than two standard deviations above the mean, or a value greater than",
"    <span class=\"nowrap\">",
"     7700/microL",
"    </span>",
"    in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31303?source=see_link\">",
"     \"Definition and mechanisms of leukocytosis and neutrophilia\"",
"    </a>",
"    .) The ANC is equal to the product of the white blood cell count (WBC) and the percentage of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis:",
"   </p>",
"   <p>",
"    ANC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    &nbsp;= &nbsp;WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    &nbsp;x &nbsp;percent (PMNs &nbsp;+ &nbsp;bands) &divide; 100",
"   </p>",
"   <p>",
"    An ANC above",
"    <span class=\"nowrap\">",
"     7700/microL",
"    </span>",
"    in patient with a total WBC less than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    is called isolated neutrophilia. An example of a setting in which this might occur is the patient with AIDS in whom an increase in neutrophils may be offset by the lymphopenia. However, for the purposes of this discussion, neutrophilia will be synonymous with neutrophilic leukocytosis.",
"   </p>",
"   <p>",
"    Granulocytosis is generally used interchangeably with neutrophilia, although they are somewhat different. Granulocytosis can also reflect an increased white blood cell count due to increased numbers of eosinophils or basophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SPURIOUS LEUKOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before reviewing the causes of true neutrophilia, it is important to exclude artifacts which spuriously raise the observed WBC. This problem can be due to blood sampling problems or can occur in certain primary disease states.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Platelet clumping",
"    </span>",
"    &nbsp;&mdash;&nbsp;If anticoagulation is inadequate, the resulting platelet clumps can be counted as leukocytes by automated cell counters. In these circumstances, the WBC count is rarely increased by more than 10 percent and there is usually an associated spurious thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, approximately 0.1 percent of normal subjects have EDTA-dependent agglutinins which can also lead to platelet clumping and spurious leukocytosis (also called pseudoleukocytosis) (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"mobipreview.htm?26/15/26872\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cryoglobulinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cold-insoluble plasma proteins are present, a temperature-dependent increase in leukocyte and platelet counts occurs at temperatures of 30&deg;C or less. This can result in WBC counts as high as",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    and a doubling of the platelet count, both of which are attributed to various sizes of precipitated cryoglobulin particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/3\">",
"     3",
"    </a>",
"    ]. This effect is increased if the sample is allowed to cool to lower temperatures and disappears if the sample is kept at body temperature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRIMARY NEUTROPHILIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilia, often with a left shift, can be indicative of a primary disease of the neutrophil system or abnormal regulation of neutrophil production (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"mobipreview.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hereditary neutrophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An autosomal dominant condition leading to neutrophilia has been described in at least eight affected members of two families, with the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukocyte counts chronically in the 20,000 to more than",
"      <span class=\"nowrap\">",
"       100,000/microL",
"      </span>",
"      range",
"     </li>",
"     <li>",
"      Splenomegaly, often massive, occasionally requiring splenectomy",
"     </li>",
"     <li>",
"      Elevated leukocyte alkaline phosphatase scores",
"     </li>",
"     <li>",
"      Widened diploe of the skull",
"     </li>",
"     <li>",
"      Normal neutrophil function and",
"      <span class=\"nowrap\">",
"       CD18/CD11b",
"      </span>",
"      surface expression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No apparent propensity to bacterial infection has been reported and none of the family members has had any serious medical problems other than a bleeding diathesis related to platelet dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chronic idiopathic neutrophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic neutrophilia can occur in subjects who are otherwise well. One report described 34 otherwise healthy subjects with total leukocyte counts of 11,000 to",
"    <span class=\"nowrap\">",
"     40,000/microL,",
"    </span>",
"    with the remainder of their blood counts being normal, other than occasional thrombocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/5\">",
"     5",
"    </a>",
"    ]. Bone marrow aspirations and leukocyte alkaline phosphatase scores were normal. They were followed for more than 20 years with no apparent medical problems becoming evident.",
"   </p>",
"   <p>",
"    These data are a reminder that certain normal subjects will fall outside the normal range with respect to WBC count and should be considered normal, sparing them extensive evaluations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pelger-Huet anomaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Pelger-Huet anomaly is a benign dominantly inherited defect of terminal neutrophil differentiation with a frequency at birth of 1:6000, due to mutations in the lamin B-receptor gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. An unusual case of Pelger-Huet anomaly has been reported in association with four generations of one family with late-onset progressive proximal muscular dystrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Pelger-Huet anomaly can give rise to an apparent increase in neutrophil band forms, often confused with a left shift. Most neutrophils in heterozygotes have nuclei with only two lobes and excessively coarse clumping of nuclear chromatin. The two lobes are joined by a thin bridge that is much thinner than that seen in a normal band form. (",
"    <a class=\"graphic graphic_picture graphicRef71990 \" href=\"mobipreview.htm?4/45/4816\">",
"     picture 2",
"    </a>",
"    ). These cells function normally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/9\">",
"     9",
"    </a>",
"    ]. The homozygous state results in neutrophils that contain a single round eccentric nucleus with clumped chromatin.",
"   </p>",
"   <p>",
"    Pelger-Huet cells can develop multiple lobes during states of vitamin B12 or folate deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/10\">",
"     10",
"    </a>",
"    ]. The cells return to their bilobate state once the vitamin deficiency is corrected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    and sulfonamides can induce the anomaly reversibly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This so-called pseudo-Pelger cell has also been reported transiently during certain acute infections, in acute and chronic myeloid leukemia, and in myelofibrosis. This cell is especially prominent in the myelodysplastic syndromes, where this finding represents acquired defective maturation within the granulocyte series. Eosinophils, which are normally bilobed, and basophils may also be involved in this process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of a leukemoid reaction (WBC count",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL)",
"    </span>",
"    due to neutrophilia are severe infection, all-trans retinoic acid therapy, the administration of recombinant hematopoietic growth factors, and chronic myeloid leukemia (CML). CML in adults may be distinguished from a leukemoid reaction by presence of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low leukocyte alkaline phosphatase (LAP) score (in contrast to the high values typically seen in infection and polycythemia vera)",
"     </li>",
"     <li>",
"      Presence of a greater percent of myelocytes than metamyelocytes on the WBC differential (\"leukemic hiatus\").",
"     </li>",
"     <li>",
"      Presence of the Philadelphia chromosome (reciprocal translocation between chromosomes 9 and 22) on karyotypic analysis of the bone marrow, or molecular analysis for the bcr-abl fusion product of the CML translocation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other myeloproliferative disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilia also may be seen in the other myeloproliferative disorders including polycythemia vera, agnogenic myeloid metaplasia, and essential thrombocythemia. In polycythemia vera, the increase in red cell mass and usual elevation in LAP score are distinguishing features from CML (",
"    <a class=\"graphic graphic_table graphicRef62788 \" href=\"mobipreview.htm?25/50/26411\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9738?source=see_link\">",
"     \"Diagnostic approach to the patient with suspected polycythemia vera\"",
"    </a>",
"    .) In agnogenic myeloid metaplasia, the primary features are marked splenomegaly and a leukoerythroblastic blood picture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Familial myeloproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A syndrome of growth retardation, hepatosplenomegaly, anemia and leukocytosis has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/13\">",
"     13",
"    </a>",
"    ]. All subjects had low LAP scores. Chromosomal analysis revealed no significant consistent abnormalities, and no subject had a Philadelphia chromosome. Some affected children died in early life, while others remained stable or improved. Several other members, in four generations of the family, had low LAP scores but no other findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Congenital anomalies and leukemoid reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemoid reactions have been associated with amegakaryocytic thrombocytopenia and with congenital deformities such as tetralogy of Fallot, dextrocardia and absent radii, and rudimentary little toes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with Down syndrome (trisomy of chromosome 21) may have transient leukemoid reactions that resemble congenital acute leukemia or chronic myeloid leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/16\">",
"     16",
"    </a>",
"    ]. Affected children can also have exaggerated leukemoid responses to stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/17\">",
"     17",
"    </a>",
"    ]. The mechanism by which this occurs is unclear.",
"   </p>",
"   <p>",
"    Transient leukemoid reactions simulating acute leukemia have also been seen in three phenotypically normal children who expressed trisomy 21 mosaicism in myeloid cells but not in skin fibroblasts. The chromosomal abnormalities disappeared after the leukemoid reaction resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Leukocyte adhesion deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small group of patients have been described with persistent leukocytosis, delayed separation of the umbilical cord, recurrent infections, and a stimulus-dependent activation defect of neutrophils. Neutrophils from these patients lack CD18 and therefore do not express any leukocyte or beta-2 integrins. This disorder is referred to as leukocyte adhesion deficiency type I (LAD I). A few other patients with similar and clinical laboratory findings have been described to have neutrophils lacking sialyl Lewis X, the ligand for L-selectin (LAD II) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One leukocyte integrin is the surface receptor for the inactivated third component of complement (C3bi); neutrophils from patients with LAD I show defects in chemotaxis, adherence, and phagocytosis of C3bi-coated particles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Familial cold autoinflammatory syndrome and Muckle-Wells syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial cold autoinflammatory syndrome, also called familial cold urticaria, and the Muckle-Wells syndrome are two rare familial causes of neutrophilia. These disorders are discussed in detail separately, but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=see_link\">",
"     \"Cryopyrin-associated periodic syndromes and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial cold autoinflammatory syndrome is characterized by episodes fever, leukocytosis, urticaria, rash, conjunctivitis, and muscle and skin tenderness after exposure to cold. Urticaria followed by fever starts about seven hours after cold exposure. Leukocytosis, sometimes to above",
"    <span class=\"nowrap\">",
"     30,000/microL,",
"    </span>",
"    starts about 10 hours after cold exposure and begins to subside 12 to 14 hours later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The Muckle-Wells syndrome has a similar phenotype except for lack of cold sensitivity and frequent sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both disorders are associated with mutations in a gene encoding for a protein called cryopyrin, which is a leukocyte-specific member of the pyrin superfamily that may play a role in the regulation of apoptosis in a subset of leukocytes involved in the early steps of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/25-27\">",
"     25-27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SECONDARY NEUTROPHILIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilia can arise secondary to ongoing processes, such as smoking, infection, inflammation, medications, stress, and malignancy. This condition is called secondary or reactive neutrophilia (secondary or reactive leukocytosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most common cause of mild neutrophilia is cigarette smoking. It has been estimated that the WBC count in smokers is raised by about 25 percent, with an approximate doubling in the ANC in subjects who smoke two packs per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. While the total WBC may stay elevated for up to five years after cessation of smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/28,30\">",
"     28,30",
"    </a>",
"    ], other observations have indicated normalization within one to two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The mechanism underlying this phenomenon is unknown, although smoking-related inflammation has been suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest leukocytosis with a left shift (ie, presence of increased numbers of cells of the granulocyte series less mature than the neutrophil) is commonly seen in association with many acute bacterial infections. On the other hand, overwhelming infection can occasionally lead to depletion of the marrow's storage pool, resulting in neutropenia rather than neutrophilia. This is frequently noted in the preterm infant with overwhelming infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, leukocytosis is commonly seen in association with acute otitis media. In one series in children, 9 percent had a WBC count",
"    <span class=\"nowrap\">",
"     &gt;20,000/microL,",
"    </span>",
"    while 27 percent had counts below the mean for age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/35\">",
"     35",
"    </a>",
"    ]. The predictive value of leukocytosis and increased band forms (WBC",
"    <span class=\"nowrap\">",
"     &gt;15,000/microL",
"    </span>",
"    and band forms",
"    <span class=\"nowrap\">",
"     &gt;200/microL)",
"    </span>",
"    in detecting bacterial infection was increased from 32 percent to 71 percent when decreased fibronectin levels (1 SD below mean for age) were also present. This finding is of particular interest in view of the role of fibronectin in promoting phagocytosis by neutrophils and monocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute infection should be particularly suspected in patients with a total WBC count",
"    <span class=\"nowrap\">",
"     &gt;25,000/microL.",
"    </span>",
"    This was illustrated in a study of 54 such patients presenting to an emergency department who were compared with 118 age-matched controls who presented with moderate leukocytosis (WBC 12,000 to",
"    <span class=\"nowrap\">",
"     25,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/37\">",
"     37",
"    </a>",
"    ]. The patients with extreme leukocytosis were significantly more likely to have an infectious disease (74 versus 48 percent) and had a higher mortality rate.",
"   </p>",
"   <p>",
"    Certain bacteria (eg, pneumococcus, staphylococcus, clostridial species) may cause particularly high leukocyte counts. Neutrophilia may be present in children with leptospiral infections, certain viral infections (Herpes simplex, varicella), advanced tuberculosis, and mononucleosis (particularly in the child younger than five years). Neutrophilia has also been observed in children with Kawasaki disease.",
"   </p>",
"   <p>",
"    With respect to Clostridia infections, a leukemoid reaction is commonly seen in patients with Clostridium sordellii infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, unexplained leukocytosis in hospitalized patients, even without diarrhea, may represent a harbinger of C. difficile infection, which usually occur after 5 to 10 days of antibiotic treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=see_link&amp;anchor=H2#H2\">",
"     \"Clostridial myonecrosis\", section on 'Spectrum of clostridial infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=see_link&amp;anchor=H2#H2\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The acute elevation in the neutrophil count that may be seen with infection is due to the release of mature neutrophils and band forms from the marrow storage pool and the marginated pool, which can occur within minutes to hours. Epinephrine release may contribute to this response by diminishing neutrophil adherence to endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/39\">",
"     39",
"    </a>",
"    ]. Granulocyte production also may be increased due in part to the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pentapeptide pEEDCK (pGlu-Glu-Asp-Cys-Lys) is associated with mature leukocytes and maintains murine pluripotent hematopoietic stem cells (CFU-S) in a quiescent state under physiologic conditions. However, PMNs undergoing a respiratory burst oxidize pEEDCK to a disulfide-bonded homodimer, which stimulates CFU-S proliferation in vivo, providing a positive signal for increasing stem cell proliferation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/40\">",
"       40",
"      </a>",
"      ]. Thus, clinical settings such as infection that require increased hematopoiesis are associated sequentially with granulocyte and macrophage activation and the formation of dimer from endogenous pEEDCK monomer, providing a rapid signal for increasing stem cell proliferation and blood cell production.",
"     </li>",
"     <li>",
"      The leukemoid reaction seen with C. sordellii infection is mediated in part by C. sordellii neuraminidase, which directly stimulates promyelocyte cell proliferation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/38\">",
"       38",
"      </a>",
"      ]. The neuraminidase also affects vascular cell adhesion molecule 1, which promotes the release of mature and immature granulocytes from bone marrow stromal cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1431?source=see_link\">",
"       \"Toxic shock syndrome due to Clostridium sordellii\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reaction to infections or inflammation may also be accompanied by the presence of toxic granulation, Dohle bodies, and cytoplasmic vacuoles in the neutrophils (",
"    <a class=\"graphic graphic_picture graphicRef70248 \" href=\"mobipreview.htm?7/17/7449\">",
"     picture 3",
"    </a>",
"    ). The usefulness of these findings for diagnosing the presence of infectious or inflammatory disease (ID) was studied in 292 patients, using an elevated level of C-reactive protein as the gold standard for the presence of ID [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/41\">",
"     41",
"    </a>",
"    ]. The results indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The highest specificity for the presence of ID (79 percent) was found when band forms comprised &ge;20 percent of the total WBC",
"     </li>",
"     <li>",
"      The presence of Dohle bodies, toxic granulation, and cytoplasmic vacuoles had a high sensitivity (80 percent) but a low specificity (58 percent) for predicting ID.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammatory processes result in stimulation of granulocyte production. Examples include juvenile onset rheumatoid arthritis, Kawasaki's disease (in which a leukemoid reaction can occur), rheumatoid arthritis in adults, and adult Still's disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/42\">",
"     42",
"    </a>",
"    ]. Patients with Crohn's disease, ulcerative colitis, granulomatous infections, bronchiectasis or chronic hepatitis may develop leukocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutrophilia, particularly with disease flare-ups. One study of 87 noncystic fibrosis bronchiectasis patients showed that the neutrophil count was the best correlate for active inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/43\">",
"     43",
"    </a>",
"    ]. In another study of 110 patients at risk for recurrence of Crohn's disease following surgery, preoperative leukocytosis was significantly associated with recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Effect of proinflammatory cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of proinflammatory cytokines are involved in the chronic inflammatory process, including tumor necrosis factor (TNF)-alpha,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF), granulocyte-monocyte colony-stimulating factor (GM-CSF), MIP-2, interleukin (IL)-1-beta, IL-6, and IL-8. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .) Each of these proinflammatory cytokines appears to have distinct effects on the inflammatory response and possible associated neutrophilia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blockade of the IL-1 receptor interferes with the ability of IL-1 to stimulate egress of neutrophils from the bone marrow and to induce neutrophilia in mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-6 deficient mice respond to endotoxin with more pronounced circulating levels of TNF-alpha, MIP-2, GM-CSF, and interferon gamma, supporting a modulating role for IL-6 in controlling other proinflammatory cytokines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL- 8 specifically attracts and activates neutrophils. Mice rendered deficient in the IL-8 receptor accumulated granulocytes (and B-lymphocytes) in lymph nodes and spleen; however, blood neutrophils could not migrate to sites of inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/47\">",
"       47",
"      </a>",
"      ]. These and other studies raise the possibility that IL-8 may serve as a novel target for therapeutic intervention in neutrophil-mediated inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GM-CSF at a dose of 250",
"      <span class=\"nowrap\">",
"       mcg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      administered to seven human normal volunteers for up to 14 days raised their blood neutrophil counts 3.5 times baseline by accelerating neutrophil release from the bone marrow and reducing neutrophil migration to tissue sites of inflammation; there was little or no effect on neutrophil production or blood half-life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6185?source=see_link\">",
"       \"Normal neutrophil development and kinetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      G-CSF at a dose of 10",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day administered to 26 healthy individuals for five to six consecutive days raised their blood neutrophil counts 12 times baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/50\">",
"       50",
"      </a>",
"      ]. Treatment was associated with evidence for transient in vivo activation of neutrophils, including increases in surface expression of integrins",
"      <span class=\"nowrap\">",
"       (CD11b/CD18),",
"      </span>",
"      plasma elastase antigen levels, and neutrophil cellular elastase activity. Markers of endothelial cell activation, such as plasma levels of von Willebrand factor and thrombomodulin also were increased, as were markers of hypercoagulation such as plasma levels of D-dimer, prothrombin fragment F1+ 2, and thrombin-antithrombin complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Stress neutrophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A modest elevation in the neutrophil count has been associated with many types of \"stress.\" Neutrophilia can occur within minutes of exercise, stress, or epinephrine injection and is presumed to be related to the movement of neutrophils from the marginated pool into the circulating pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/39,51,52\">",
"     39,51,52",
"    </a>",
"    ]. With epinephrine, this effect is mediated by reduced neutrophil adherence and can be blocked in vivo with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    and in vitro with anti-cyclic AMP antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;A different mechanism appears to be involved with exercise-induced neutrophilia which is not blocked by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , despite measurable increases in plasma epinephrine postexercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/53\">",
"     53",
"    </a>",
"    ]. The neutrophilia in this setting is directly related to workload and cardiac output, suggesting a larger role for mechanical and flow-related effects on dislodgement of the leukocytes sequestered in the lung. On the other hand, the delayed leukocytosis (&le;235 percent increase at five hours postexercise) may be related to marrow release of leukocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. The latter response is not associated with the release of early granulocyte precursors in the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;An interesting association between the leukocyte count and myocardial infarction has been described. In one study, subjects with a leukocyte count above",
"    <span class=\"nowrap\">",
"     9000/microL",
"    </span>",
"    had a 4.5-fold higher incidence of myocardial infarction than those with a leukocyte count of below",
"    <span class=\"nowrap\">",
"     6000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/55\">",
"     55",
"    </a>",
"    ]. Another study, which corrected for smoking, found that for each decrease in WBC count of",
"    <span class=\"nowrap\">",
"     1000/microL,",
"    </span>",
"    the risk for fatal coronary heart disease fell by 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear whether the increased WBC count is an additional risk factor or merely an indicator of chronic stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/56\">",
"     56",
"    </a>",
"    ]. Another possibility is that the neutrophilia reflects chronic inflammation which may contribute to the atherosclerotic process. Consistent with this hypothesis is the observation that elevations in the serum concentration of the acute phase reactant C-reactive protein also have predictive value for coronary disease (",
"    <a class=\"graphic graphic_figure graphicRef56104 \" href=\"mobipreview.htm?14/23/14718\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilia has been associated with a variety of other stressful states:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newborns for the first three days post-delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mild neutrophilia and lymphopenia have been associated with unipolar depression but may be related to the use of antidepressants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neutrophilia is seen during the postoperative period, with the neutrophil count doubling approximately three hours after surgery. This response does not seem to be related to the type of anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient neutrophilia is often seen following seizures",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Glucocorticoids and other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis has been seen in association with a number of drugs and drug reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoid therapy is associated with a low-grade neutrophilia. The mean increase in ANC at",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      doses of 40 to 80",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is about",
"      <span class=\"nowrap\">",
"       4000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/62\">",
"       62",
"      </a>",
"      ]. This effect is mediated by reduced neutrophil adhesion and by increased release from marrow stores. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31303?source=see_link&amp;anchor=H14#H14\">",
"       \"Definition and mechanisms of leukocytosis and neutrophilia\", section on 'Glucocorticoids and other agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta-agonists such as epinephrine produce an acute neutrophilia by releasing neutrophils from the marginated pool [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/63\">",
"       63",
"      </a>",
"      ]. This is similar to the stress-induced neutrophilic response described above.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      produces leukocytosis by increasing the production of colony stimulating factors; it has been used with varying success to treat several neutropenic states [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recombinant colony stimulating factors, such as rG-CSF and rGM-CSF are commercially available for increasing neutrophil counts in neutropenic patients undergoing chemotherapy. Absolute neutrophil counts above",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      can be regularly induced by their use.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Differentiation syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 25 percent of patients with acute promyelocytic leukemia treated with tretinoin (all-trans retinoic acid, ATRA) have experienced a syndrome called the differentiation syndrome (previously retinoic acid syndrome). This consists of fever, dyspnea, weight gain, pulmonary infiltrates, pleural or pericardial effusions, episodic hypotension, renal dysfunction. The pathogenesis is unknown but may be related to a capillary leak syndrome induced by the release of cytokines from differentiating malignant promyelocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37384?source=see_link\">",
"     \"Differentiation (retinoic acid) syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During treatment with ATRA, up to 50 percent of patients will develop rapidly evolving leukocytosis, which is associated with a higher risk of life-threatening complications. The association between leukocytosis and the differentiation syndrome is unclear, although they often occur together [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/65\">",
"     65",
"    </a>",
"    ]. The hyperleukocytosis probably results from cellular maturation and may result in leukostasis. Complications are uncertain and management is controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link&amp;anchor=H19#H19\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Differentiation syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link&amp;anchor=H20#H20\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Hyperleukocytosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=see_link\">",
"     \"Hyperleukocytosis and leukostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Marrow stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant leukocytosis can be seen in states of chronic stimulation of the bone marrow, such as hemolytic anemia or immune thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/66\">",
"     66",
"    </a>",
"    ]. As an example, patients with sickle cell anemia commonly have leukocyte counts in the 12,000 to",
"    <span class=\"nowrap\">",
"     15,000/microL",
"    </span>",
"    range and have an exaggerated elevation in WBC counts with infection or vasoocclusive crises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/67\">",
"     67",
"    </a>",
"    ]. This response may be further augmented by the functional asplenia (see below) commonly seen in sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Significant rebound leukocytosis, lasting several weeks, can also occur during the recovery phase of marrow suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In one extreme instance, 90 percent myeloblasts were transiently found in the bone marrow and as many as 20 percent myeloblasts in the peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Marrow invasion and leukoerythroblastic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilia associated with the presence of circulating immature granulocytes, nucleated red cells, and teardrop-shaped erythrocytes, with or without thrombocytosis (leukoerythroblastic reaction), may be seen when the marrow is directly invaded by tumor, fibrosis, or granulomatous reactions (",
"    <a class=\"graphic graphic_picture graphicRef68110 graphicRef55274 \" href=\"mobipreview.htm?18/50/19242\">",
"     picture 4A-B",
"    </a>",
"    ). A bone marrow aspiration and biopsy, performed to look for tumor clumps, fibrosis, granulomata, or culture for fungus or mycobacteria, is indicated in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/72\">",
"     72",
"    </a>",
"    ]. A leukoerythroblastic reaction can also be transiently seen during recovery from severe myelosuppression and may be the initial presentation of transient erythroblastopenia of childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nonhematologic malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis is frequently associated with solid tumors, particularly large cell lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/74\">",
"     74",
"    </a>",
"    ]. The elevation in WBC count seen with solid tumors is usually modest, in the 12,000 to",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. However, counts as high as",
"    <span class=\"nowrap\">",
"     115,000/microL",
"    </span>",
"    occur; this can be seen in the absence of marrow metastasis or in patients with marrow involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16282?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\", section on 'Paraneoplastic phenomena'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of extreme leukocytosis was explored in a retrospective study of 758 patients with solid tumors and a total white blood cell count",
"    <span class=\"nowrap\">",
"     &gt;40,000/microL.",
"    </span>",
"    The following causes were identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Use of hematopoietic growth factors &mdash; 69 percent",
"     </li>",
"     <li>",
"      Infection &mdash; 15 percent",
"     </li>",
"     <li>",
"      Paraneoplastic leukemoid reaction &mdash; 10 percent",
"     </li>",
"     <li>",
"      High-dose glucocorticoid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vasopressor use &mdash; 5 percent",
"     </li>",
"     <li>",
"      Newly-diagnosed leukemia &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Paraneoplastic leukemoid reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the above-noted study, nearly all of the 77 patients with paraneoplastic leukemoid reaction had either a large, bulky primary tumor or widely metastatic disease. Their short-term prognosis was poor, with the vast majority dying within 12 weeks of their initial extreme leukocyte count.",
"   </p>",
"   <p>",
"    The mechanisms of paraneoplastic leukemoid reaction are not well understood. In addition to bone marrow invasion and inflammation, some solid tumors have been shown to secrete substances with colony-stimulating activity (eg, G-CSF, GM-CSF, macrophage CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. In murine models, both G-CSF and macrophage CSF have been isolated from tumors associated with marked neutrophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Sweet syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sweet syndrome, also called acute febrile neutrophilic dermatosis, is characterized by fever, neutrophilia, and the abrupt appearance of erythematous, painful, cutaneous plaques, primarily on the upper extremities, head, and neck. It is associated with a variety of underlying conditions including malignancy in 20 to 25 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=see_link\">",
"     \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Heatstroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;WBC counts as high as",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    have been seen in heatstroke. Up to 50 percent of the neutrophils have nuclei with segments smaller than usual, resembling a clustering of grapes around a central stem (ie, botryoid or grape-like nuclei) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Asplenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate neutrophilia is often associated with asplenia, whether it is related to congenital disease (eg, dextrocardia), acquired disease (eg, autoinfarction in sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/85\">",
"     85",
"    </a>",
"    ]), or following surgical removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/55/35705/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27325535\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilic leukocytosis is defined as a total white blood cell count greater than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    plus an absolute neutrophil count (ANC) greater than",
"    <span class=\"nowrap\">",
"     7700/microL",
"    </span>",
"    in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31303?source=see_link\">",
"     \"Definition and mechanisms of leukocytosis and neutrophilia\"",
"    </a>",
"    .) Neutrophilia can be either primary (inherited) or acquired (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"mobipreview.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27325581\">",
"    <span class=\"h2\">",
"     Causes of primary neutrophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of inherited thrombophilia include the following. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Primary neutrophilia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hereditary neutrophilia",
"     </li>",
"     <li>",
"      Familial myeloproliferative disease",
"     </li>",
"     <li>",
"      Congenital anomalies and leukemia",
"     </li>",
"     <li>",
"      Down syndrome",
"     </li>",
"     <li>",
"      Leukocyte adhesion deficiency",
"     </li>",
"     <li>",
"      Familial cold autoinflammatory syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27325604\">",
"    <span class=\"h2\">",
"     Causes of acquired neutrophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired neutrophilia is more common than primary neutrophilia. The most common causes of acquired neutrophilia include the following. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Secondary neutrophilia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Stress, exercise, trauma",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Acute/chronic",
"      </span>",
"      infection or inflammation",
"     </li>",
"     <li>",
"      Drugs (eg, glucocorticoids, epinephrine, granulocyte or granulocyte-macrophage colony-stimulating factor)",
"     </li>",
"     <li>",
"      Myeloproliferative neoplasms (CML, PV, ET, PMF)",
"     </li>",
"     <li>",
"      Spurious (eg, platelet clumping, presence of cryoglobulins). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Spurious leukocytosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2072741\">",
"    <span class=\"h2\">",
"     Approach to the patient with neutrophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link\">",
"     \"Approach to the patient with neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/1\">",
"      Solanki DL, Blackburn BC. Spurious leukocytosis and thrombocytopenia. A dual phenomenon caused by clumping of platelets in vitro. JAMA 1983; 250:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/2\">",
"      Savage RA. Pseudoleukocytosis due to EDTA-induced platelet clumping. Am J Clin Pathol 1984; 81:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/3\">",
"      Patel KJ, Hughes CG, Parapia LA. Pseudoleucocytosis and pseudothrombocytosis due to cryoglobulinaemia. J Clin Pathol 1987; 40:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/4\">",
"      Herring WB, Smith LG, Walker RI, Herion JC. Hereditary neutrophilia. Am J Med 1974; 56:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/5\">",
"      Ward HN, Reinhard EH. Chronic idiopathic leukocytosis. Ann Intern Med 1971; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/6\">",
"      Hoffmann K, Dreger CK, Olins AL, et al. Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Hu&euml;t anomaly). Nat Genet 2002; 31:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/7\">",
"      Best S, Salvati F, Kallo J, et al. Lamin B-receptor mutations in Pelger-Hu&euml;t anomaly. Br J Haematol 2003; 123:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/8\">",
"      Schneiderman LJ, Sampson WI, Schoene WC, Haydon GB. Genetic studies of a family with two unusual autosomal dominant conditions: muscular dystrophy and Pelger-Huet anomaly. Clinical, pathologic and linkage considerations. Am J Med 1969; 46:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/9\">",
"      Johnson CA, Bass DA, Trillo AA, et al. Functional and metabolic studies of polymorphonuclear leukocytes in the congenital Pelger-Huet anomaly. Blood 1980; 55:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/10\">",
"      Taylor RL. Pelger-Hu&euml;t anomaly and megaloblastic anemia. Am J Clin Pathol 1973; 60:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/11\">",
"      DORR AD, MOLONEY WC. Acquired pseudo-Pelger anomaly of granulocytic leukocytes. N Engl J Med 1959; 261:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/12\">",
"      Kaplan JM, Barrett O Jr. Reversible pseudo-Pelger anomaly related to sulfisoxazole therapy. N Engl J Med 1967; 277:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/13\">",
"      Randall DL, Reiquam CW, Githens JH, Robinson A. Familial myeloproliferative disease. A new syndrome closely simulating myelogenous leukemia in childhood. Am J Dis Child 1965; 110:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/14\">",
"      EMERY JL, GORDON RR, RENDLESHORT J, et al. Congenital amegakaryocytic thrombocytopenia with congenital deformities and a leukemoid blood picture in the newborn. Blood 1957; 12:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/15\">",
"      Dignan PS, Mauer AM, Frantz C. Phocomelia with congenital hypoplastic thrombocytopenia and myeloid leukemoid reactions. J Pediatr 1967; 70:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/16\">",
"      Weinstein HJ. Congenital leukaemia and the neonatal myeloproliferative disorders associated with Down's syndrome. Clin Haematol 1978; 7:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/17\">",
"      Rubins J, Wakem CJ. Hypoglycemia and leukemoid reaction with hypernephroma. N Y State J Med 1977; 77:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/18\">",
"      Brodeur GM, Dahl GV, Williams DL, et al. Transient leukemoid reaction and trisomy 21 mosaicism in a phenotypically normal newborn. Blood 1980; 55:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/19\">",
"      Jones GR, Weaver M, Laug WE. Transient blastemia in phenotypically normal newborns. Am J Pediatr Hematol Oncol 1987; 9:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/20\">",
"      Etzioni A, Harlan JM, Pollack S, et al. Leukocyte adhesion deficiency (LAD) II: a new adhesion defect due to absence of sialyl Lewis X, the ligand for selectins. Immunodeficiency 1993; 4:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/21\">",
"      Fischer A, Lisowska-Grospierre B, Anderson DC, Springer TA. Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodefic Rev 1988; 1:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/22\">",
"      Tindall JP, Beeker SK, Rosse WF. Familial cold urticaria. A generalized reaction involving leukocytosis. Arch Intern Med 1969; 124:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/23\">",
"      Doeglas HM, Bleumink E. Familial cold urticaria. Clinical findings. Arch Dermatol 1974; 110:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/24\">",
"      Muckle TJ. The 'Muckle-Wells' syndrome. Br J Dermatol 1979; 100:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/25\">",
"      Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/26\">",
"      Kastner DL, O'Shea JJ. A fever gene comes in from the cold. Nat Genet 2001; 29:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/27\">",
"      Lokuta MA, Cooper KM, Aksentijevich I, et al. Neutrophil chemotaxis in a patient with neonatal-onset multisystem inflammatory disease and Muckle-Wells syndrome. Ann Allergy Asthma Immunol 2005; 95:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/28\">",
"      Parry H, Cohen S, Schlarb JE, et al. Smoking, alcohol consumption, and leukocyte counts. Am J Clin Pathol 1997; 107:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/29\">",
"      Schwartz J, Weiss ST. Cigarette smoking and peripheral blood leukocyte differentials. Ann Epidemiol 1994; 4:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/30\">",
"      Kawada T. Smoking-induced leukocytosis can persist after cessation of smoking. Arch Med Res 2004; 35:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/31\">",
"      Van Tiel E, Peeters PH, Smit HA, et al. Quitting smoking may restore hematological characteristics within five years. Ann Epidemiol 2002; 12:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/32\">",
"      Abel GA, Hays JT, Decker PA, et al. Effects of biochemically confirmed smoking cessation on white blood cell count. Mayo Clin Proc 2005; 80:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/33\">",
"      Fr&ouml;hlich M, Sund M, L&ouml;wel H, et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/34\">",
"      Christensen RD, Rothstein G, Anstall HB, Bybee B. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature marrow neutrophils. Pediatrics 1982; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/35\">",
"      Schwartz RH, Hayden GF, Rodriguez WJ, et al. Leukocyte counts in children with acute otitis media. Pediatr Emerg Care 1986; 2:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/36\">",
"      Koenig JM, Patterson LE, Rench MA, Edwards MS. Role of fibronectin in diagnosing bacterial infection in infancy. Am J Dis Child 1988; 142:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/37\">",
"      Lawrence YR, Raveh D, Rudensky B, Munter G. Extreme leukocytosis in the emergency department. QJM 2007; 100:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/38\">",
"      Aldape MJ, Bryant AE, Ma Y, Stevens DL. The leukemoid reaction in Clostridium sordellii infection: neuraminidase induction of promyelocytic cell proliferation. J Infect Dis 2007; 195:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/39\">",
"      Boxer LA, Allen JM, Baehner RL. Diminished polymorphonuclear leukocyte adherence. Function dependent on release of cyclic AMP by endothelial cells after stimulation of beta-receptors by epinephrine. J Clin Invest 1980; 66:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/40\">",
"      Paukovits WR, Paukovits JB, Moser MH, et al. Activated granulocytes oxidize the endogenous stem cell inhibitory peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK) to the stimulatory dimer: a redox-mediated mechanism for demand-induced hematopoietic regulation. Exp Hematol 1998; 26:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/41\">",
"      Seebach JD, Morant R, R&uuml;egg R, et al. The diagnostic value of the neutrophil left shift in predicting inflammatory and infectious disease. Am J Clin Pathol 1997; 107:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/42\">",
"      Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 1991; 70:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/43\">",
"      Wilson CB, Jones PW, O'Leary CJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998; 12:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/44\">",
"      Caprilli R, Corrao G, Taddei G, et al. Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Dis Colon Rectum 1996; 39:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/45\">",
"      McIntyre KW, Stepan GJ, Kolinsky KD, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/46\">",
"      Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/47\">",
"      Cacalano G, Lee J, Kikly K, et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994; 265:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/48\">",
"      Mukaida N, Matsumoto T, Yokoi K, et al. Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8). Inflamm Res 1998; 47 Suppl 3:S151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/49\">",
"      Dale DC, Liles WC, Llewellyn C, Price TH. Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol 1998; 57:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/50\">",
"      Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/51\">",
"      Christensen RD, Hill HR. Exercise-induced changes in the blood concentration of leukocyte populations in teenage athletes. Am J Pediatr Hematol Oncol 1987; 9:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/52\">",
"      Christensen RD, Rothstein G. Pitfalls in the interpretation of leukocyte counts of newborn infants. Am J Clin Pathol 1979; 72:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/53\">",
"      Foster NK, Martyn JB, Rangno RE, et al. Leukocytosis of exercise: role of cardiac output and catecholamines. J Appl Physiol 1986; 61:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/54\">",
"      McCarthy DA, Perry JD, Melsom RD, Dale MM. Leucocytosis induced by exercise. Br Med J (Clin Res Ed) 1987; 295:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/55\">",
"      Zalokar JB, Richard JL, Claude JR. Leukocyte count, smoking, and myocardial infarction. N Engl J Med 1981; 304:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/56\">",
"      Fava M. Leukocytes and the risk of ischemic diseases. JAMA 1987; 258:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/57\">",
"      Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/58\">",
"      Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. J Pediatr 1979; 95:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/59\">",
"      Darko DF, Rose J, Gillin JC, et al. Neutrophilia and lymphopenia in major mood disorders. Psychiatry Res 1988; 25:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/60\">",
"      Jakobsen BW, Pedersen J, Egeberg BB. Postoperative lymphocytopenia and leucocytosis after epidural and general anaesthesia. Acta Anaesthesiol Scand 1986; 30:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/61\">",
"      Nanji AA, Freeman JB, Nair G. Postoperative leukocytosis in morbidly obese patients: relationship to serum cholesterol. Am J Hematol 1985; 20:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/62\">",
"      Dale DC, Fauci AS, Guerry D IV, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 1975; 56:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/63\">",
"      Boxer LA, Stossel TP. Effects of anti-human neutrophil antibodies in vitro. Quantitative studies. J Clin Invest 1974; 53:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/64\">",
"      Boggs DR, Joyce RA. The hematopoietic effects of lithium. Semin Hematol 1983; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/65\">",
"      Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84:3843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/66\">",
"      [Delayed post-transfusional hemolysis, leukemoid syndrome, autoimmune hemolytic anemia. Coordinating Committee for the Specific Study of Anemias under the chairmanship of H. Rochant]. Nouv Rev Fr Hematol 1987; 29:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/67\">",
"      Buchanan GR, Glader BE. Leukocyte counts in children with sickle cell disease. Comparative values in the steady state, vaso-occlusive crisis, and bacterial infection. Am J Dis Child 1978; 132:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/68\">",
"      Deubelbeiss KA, Roth P. Postmitotic marrow neutrophils and neutrophil mobilization in man: role of the spleen. Blood 1978; 52:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/69\">",
"      MICHAELSON AK. Severe leukemoid reaction after promazine-induced agranulocytosis. J Fla Med Assoc 1959; 45:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/70\">",
"      Ruvidi�� R, Jeli�� S. Haematological aspects of drug-induced agranulocytosis. Scand J Haematol 1972; 9:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/71\">",
"      Levine PH, Weintraub LW. Pseudoleukemia during recovery from dapsone-induced agranulocytosis. Ann Intern Med 1968; 68:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/72\">",
"      Chandra J, Marwaha RK, Marwaha N, et al. Pancytopenia and leukemoid reactions in tuberculosis. Indian J Pediatr 1986; 53:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/73\">",
"      Mupanomunda OK, Alter BP. Transient erythroblastopenia of childhood (TEC) presenting as leukoerythroblastic anemia. J Pediatr Hematol Oncol 1997; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/74\">",
"      Ascensao JL, Oken MM, Ewing SL, et al. Leukocytosis and large cell lung cancer. A frequent association. Cancer 1987; 60:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/75\">",
"      Shoenfeld Y, Tal A, Berliner S, Pinkhas J. Leukocytosis in non hematological malignancies--a possible tumor-associated marker. J Cancer Res Clin Oncol 1986; 111:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/76\">",
"      Riddle PE, Dincsoy HP. Primary squamous cell carcinoma of the thyroid associated with leukocytosis and hypercalcemia. Arch Pathol Lab Med 1987; 111:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/77\">",
"      Eichenhorn MS, Van Slyck EJ. Marked mature neutrophilic leukocytosis: a leukemoid variant associated with malignancy. Am J Med Sci 1982; 284:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/78\">",
"      Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 2009; 115:3919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/79\">",
"      Obara T, Ito Y, Kodama T, et al. A case of gastric carcinoma associated with excessive granulocytosis. Production of a colony-stimulating factor by the tumor. Cancer 1985; 56:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/80\">",
"      Kojima K, Nakashima F, Boku A, et al. Clinicopathological study of involvement of granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor in non-lymphohematopoietic malignant tumors accompanied by leukocytosis. Histol Histopathol 2002; 17:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/81\">",
"      Zalom M, Hussong J, Lopez A. Carcinoma-produced granulocyte-macrophage colony stimulating factor as a cause of severe leukocytosis. Community Oncol 2012; 9:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/82\">",
"      Lee MY, Kaushansky K, Judkins SA, et al. Mechanisms of tumor-induced neutrophilia: constitutive production of colony-stimulating factors and their synergistic actions. Blood 1989; 74:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/83\">",
"      Hernandez JA, Aldred SW, Bruce JR, et al. \"Botryoid\" nuclei in neutrophils of patients with heatstroke. Lancet 1980; 2:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/84\">",
"      Ward PC, McKenna RW, Kroft SH. White blood cell changes in hyperthermia. Br J Haematol 2007; 138:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/85\">",
"      Pearson HA, Spencer RP, Cornelius EA. Functional asplenia in sickle-cell anemia. N Engl J Med 1969; 281:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/86\">",
"      McBride JA, Dacie JV, Shapley R. The effect of splenectomy on the leucocyte count. Br J Haematol 1968; 14:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/55/35705/abstract/87\">",
"      Spencer RP, McPhedran P, Finch SC, Morgan WS. Persistent neutrophilic leukocytosis associated with idiopathic functional asplenia. J Nucl Med 1972; 13:224.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8377 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35705=[""].join("\n");
var outline_f34_55_35705=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27325535\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SPURIOUS LEUKOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Platelet clumping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRIMARY NEUTROPHILIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hereditary neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chronic idiopathic neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pelger-Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other myeloproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Familial myeloproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Congenital anomalies and leukemoid reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Leukocyte adhesion deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Familial cold autoinflammatory syndrome and Muckle-Wells syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SECONDARY NEUTROPHILIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Effect of proinflammatory cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Stress neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Glucocorticoids and other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Differentiation syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Marrow stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Marrow invasion and leukoerythroblastic reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nonhematologic malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Paraneoplastic leukemoid reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Sweet syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Heatstroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Asplenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27325535\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27325581\">",
"      Causes of primary neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27325604\">",
"      Causes of acquired neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2072741\">",
"      Approach to the patient with neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8377|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/23/14718\" title=\"figure 1\">",
"      CRP, cholesterol, and future MI risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8377|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/15/26872\" title=\"picture 1\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/45/4816\" title=\"picture 2\">",
"      Pelger Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/17/7449\" title=\"picture 3\">",
"      Toxic granulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/43/30390\" title=\"picture 4A\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/37/43606\" title=\"picture 4B\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8377|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/51/30524\" title=\"table 1\">",
"      Classification of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/50/26411\" title=\"table 2\">",
"      Diagnostic criteria P vera",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=related_link\">",
"      Approach to the patient with neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24487?source=related_link\">",
"      Cryopyrin-associated periodic syndromes and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/36/31303?source=related_link\">",
"      Definition and mechanisms of leukocytosis and neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9738?source=related_link\">",
"      Diagnostic approach to the patient with suspected polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/32/37384?source=related_link\">",
"      Differentiation (retinoic acid) syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/7/19576?source=related_link\">",
"      Hyperleukocytosis and leukostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1431?source=related_link\">",
"      Toxic shock syndrome due to Clostridium sordellii",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_55_35706="ECG WPW tutorial";
var content_f34_55_35706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1142px;\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) showing the Wolff-Parkinson-White pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 222px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two main electrocardiographic features of Wolff-Parkinson-White (WPW) pattern include a short PR interval (&lt;0.12 seconds) and a delta wave (red arrows). The QRS complex is wide (&gt;0.12 seconds) and represents a fusion beat; the initial portion (delta wave) results from rapid ventricular activation via the accessory pathway (pre-excitation), while the termination of ventricular activation is via the normal conduction system leading to a fairly normal terminal portion of the QRS.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 466px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal sinus rhythm at a rate of 71 beats/min, a P wave axis of 45&deg;, and a PR interval of 0.15 sec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35706=[""].join("\n");
var outline_f34_55_35706=null;
var title_f34_55_35707="Prone improvement mechanisms";
var content_f34_55_35707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54334&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed mechanisms for prone response",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physiologic effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical result",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Improved configuration between lung and thorax",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heart is dependent",
"       </td>",
"       <td>",
"        More homogeneous Ppl gradient in ventrodorsal and cephalocaudal planes",
"       </td>",
"       <td>",
"        Improved ventilation distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Smaller volume of dependent lung",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Increased FRC (&darr; shunt)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Abdomen is unsupported*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Secretion mobilization",
"       </td>",
"       <td>",
"        Improved bronchial drainage",
"       </td>",
"       <td>",
"        Improved ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Improved aerosol delivery",
"       </td>",
"       <td>",
"        Improved effect of aerosolized meds",
"       </td>",
"       <td>",
"        Improved ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        More homogeneous perfusion",
"       </td>",
"       <td>",
"        Less dependent perfusion",
"       </td>",
"       <td>",
"        Improved V/Q matching (&darr; shunt)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Ppl: Pleural pressure; FRC: functional residual capacity; V/Q: ventilation-perfusion.",
"     <br>",
"      * Assumes prone positioning with the upper chest and pelvis supported and the abdomen suspended.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35707=[""].join("\n");
var outline_f34_55_35707=null;
var title_f34_55_35708="Parenteral iron dose";
var content_f34_55_35708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54677&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Calculation of parenteral iron dose for treatment of adults with iron deficiency anemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Required information",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body weight (kilograms) = BW",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        If patient is obese, use lean or ideal body weight*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin concentration (g/dL) = Hgb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concentration of elemental iron in the parenteral product (mg/mL) = C",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Assumptions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood volume is 65 mL per kilogram",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin concentration to be corrected to 14.0 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Each gram of hemoglobin contains 3.3 mg of iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No additional iron to be given for repletion of body stores",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intermediate calculations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood volume (dL) = 65 (mL/kg) x body weight (kg) &divide; 100 (mL/dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin deficit (g/dL) = 14.0 - patient hemoglobin concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin deficit (g) = hemoglobin deficit (g/dL) x blood volume (dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron deficit (mg) = hemoglobin deficit (g) x 3.3 (mg Fe/g Hgb)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume of parenteral iron product required (mL) = iron deficit (mg) &divide; C (mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Final calculations",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin iron deficit (mg) = BW x (14 - Hgb) x (2.145)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume of product required (mL) = BW x (14 - Hgb) x (2.145) &divide; C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Example",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 kg woman with a hemoglobin concentration of 8 g/dL. Parenteral iron product is iron sucrose (C = 20 mg elemental iron/mL).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobin iron deficit = 60 x (14 - 8) x (2.145) = 772 mg iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume of iron sucrose needed = 60 x (14 - 8) x (2.145) &divide; 20 = 38.6 mL",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Calculators are available in UpToDate to determine ideal body weight and lean body weight.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The concentration of elemental iron in the various products is, as follows: iron dextran: 50 mg/mL; iron sucrose: 20 mg/mL; ferric gluconate: 12.5 mg/mL; ferumoxytol: 30 mg/mL; ferric carboxymaltose: 50 mg/mL.",
"     <br/>",
"     &Delta; These calculations are based upon the assumptions listed above. If correction is desired for a different blood volume, final hemoglobin concentration, or for additional iron for body stores, the intermediate calculations can be employed.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     The product information sheet should be consulted in order to determine the need for a test dose, proper dilution of the product and rate of infusion, as well as the maximal suggested dose per infusion session.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35708=[""].join("\n");
var outline_f34_55_35708=null;
var title_f34_55_35709="Contents: Palliative Care";
var content_f34_55_35709=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Palliative Care",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Palliative Care",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"mobipreview.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?1/43/1726\">",
"         General principles of palliative care",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?6/13/6366\">",
"         Non pain symptoms: Assessment and management",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?9/8/9358\">",
"         Pain: Assessment and management",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?36/45/37597\">",
"         Psychosocial issues",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"mobipreview.htm?40/40/41613\">",
"         Selected end stage conditions",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?36/36/37453\">",
"         Special sites of care and allied health professions",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"mobipreview.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-64508BD83C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f34_55_35709=[""].join("\n");
var outline_f34_55_35709=null;
var title_f34_55_35710="Contents: Skin and systemic disease";
var content_f34_55_35710=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Skin and systemic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Skin and systemic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Dermatomyositis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/22/31079\">",
"           Diagnosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/9/15513\">",
"           Initial management of cutaneous dermatomyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/22/11626\">",
"           Initial treatment of dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/42/38566\">",
"           Malignancy in dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/24/38281\">",
"           Management of refractory cutaneous dermatomyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/48/13065\">",
"           Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lupus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/19/314\">",
"           Initial management of discoid lupus and subacute cutaneous lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/48/31498\">",
"           Management of refractory discoid lupus and subacute cutaneous lupus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/33/36378\">",
"           Mucocutaneous manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neutrophilic dermatoses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/43/30393\">",
"           Neutrophilic dermatoses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/17/2328\">",
"           Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/61/10202\">",
"           Pyoderma gangrenosum: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/10/21671\">",
"           Sweet syndrome (acute febrile neutrophilic dermatosis): Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/60/40905\">",
"           Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/15/27897\">",
"           Acanthosis nigricans",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/5/42073\">",
"           Cutaneous manifestations of graft-versus-host disease (GVHD)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/18/21802\">",
"           Cutaneous manifestations of internal malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/60/37832\">",
"           Epidemiology and risk factors for skin cancer in solid organ transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/52/13130\">",
"           Erythema nodosum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/8/2186\">",
"           Management of skin cancer in solid organ transplant recipients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/22/31082\">",
"           Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/45/17112\">",
"           Panniculitis: Recognition and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/10/23719\">",
"           Pathogenesis of the Raynaud phenomenon",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sarcoidosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/25/21914\">",
"           Clinical manifestations and diagnosis of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/20/19786\">",
"           Cutaneous manifestations of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/8/16522\">",
"           Management of cutaneous sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/14/6376\">",
"           Pathogenesis of sarcoidosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Scleroderma and morphea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/3/44087\">",
"           Classification of scleroderma disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/5/43095\">",
"           Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/32/39433\">",
"           Juvenile systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/1/40985\">",
"           Localized scleroderma in childhood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/34/29224\">",
"           Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/20/13642\">",
"           Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/63/19450\">",
"           Pathogenesis of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/8/133\">",
"           Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/11/37045\">",
"           Pretreatment evaluation of adults with systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/4/65\">",
"           Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/14/17640\">",
"           Treatment of morphea (localized scleroderma) in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vasculopathy and vasculitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/15/4345\">",
"           Evaluation of adults with cutaneous lesions of vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/57/30614\">",
"           Hypersensitivity vasculitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/41/10904\">",
"           Management of adults with idiopathic cutaneous small vessel vasculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F2EABC0A78-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f34_55_35710=[""].join("\n");
var outline_f34_55_35710=null;
var title_f34_55_35711="Apical 4 chamber effusion RV collapse";
var content_f34_55_35711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/66982/Apical_4chamb_eff_RV_movie.mp4?title=Apical+4+chamber+effusion+RV+collapse\" style=\"width:496px;height:368px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apical 4 chamber view of effusion and RV collapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 388px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGEAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAHBiOhIpd7f3m/OmUU7gP3t/eb86N7f3m/Om5ozRdgODNn7zfnRSL1oouwG0UUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKmtYDcSbEZQ3YHvQBLYQRTS7Z5TEpBwwXOD2z7VHdW0lu+JFxnow5B+la9v4b1GQI8MQl3HAUevv6VT1Cy1DT5niu7We3I4KOpxQBm0U8qd3II9sVcbSr4bWFpKVYZXAzkUAUlVnYKgLMegAya0IdLlL7Lk+S5HCnr+I7VJFpmq20f2n7Lc20ecCRkZPyJFSmGOJNhbluSz9TQBjOCrFT1BxTamkhK7mH3AeDUNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAE9rAZnwDgDrWxbaG05ZoJCrL26msiyKidQ7FVbgn0rr/Dt5Jpk8yRmKQnkMw3ZBoAo2era/4cm8yGWRFYY+cZVx+NdlpvjFL/AEpo7mPfcAfMkqb1OfQ9RWlpNzb6tbSWWtad9t8ziKZW2mEj0Heue1LwvDY3832GeYojBTlPmyexxQAllDagSw3emxSQzkkzYyV+npWz4atdVs7tLrQNS0uNoMvGb0jgDtg0tiL+NBEt9D86kMGj+7jsfSrVhLceH7j/AImXge31SQgMHdztC9n49aAKfi7xdq3idQmu3cl1LAhWNIolRFPfgDpXAsTI5Z42K/dwEFek63eXviZ2+z+HG02FRgR2kR2n8a43UrR4X+yLbTwyA7vnbkD0wO9AGYnh691SOee1iWOztxmSSRwNvFczIoV2CHcoPB9a9L8R2ESaPZW8scttDt3kDOZCa43ULVRsitoEijPV5Dyfr6UAYlJUkyqjlUbdjjd2NR0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFLQAqqWYAdTUrQSIu4oSPpSoEQYkX3Deta9rewqAgnwpH8a5oAyYTvYDYD2966fRbYeZHJ5TxohCO3/wBan21jZNGki3MD7mAB4Ug1ry6ZGsIkt7j9/vGAW/KgDY0fWE0PW7mxv4FuLeRQ24jlOOoxWhY3WlzXssr3DQQyN82Dyv8AtYNcrq1rePObi4tJpJigHmEcA/WlvND1OWCMQ2DxhgCWxkNn37UAdIyaeuoTx2mrAiRCWmkwA/P3a6lP+Eh/syCWy1ewgQIEViQWx/dPqK8/XwXq8Nq0k+lq1unzt5koGPxq3pzXF3EsVnpcqRxjlwS3PselAGhrMXxUL7rlp2sE4EkRVFwfpXE6oviVLtnnlV5CeWAycj1rtvNnuJFgW9uMgYVGlYKTnkYqeH+04ZBEzpDsfAa427VB9jQB5Rq9/rFzNm7uJHKjGW4/Q1hzOzMd7lj3ya9c1200gzhL7UU1W+d8k264QeozXKX0FtPNPHbWMS7f4jjgelAHFUldLc6fF+6MvkQKw6LWTdJbAN5TjavAxyWoAoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALk4xngUq443A02igCQlRnZuqWO6uQTsmkGRj73aoMfL2/OlPJG2gDWtdf1azhaKO8lEb8MjnIP4VpaX4j8QRKy22oSeQVwyk8EemDVPRdBa9lBuJTEOuMZJFdzZ6FpNtFHmbzwDkquflHfigChpOtahs87LyFDkiQkhvbFddpXjK8t7Z4rm1+zwHp5I2qT/eNY2rahYykRadaLDsXGFxkj156Vyaao/7+A7imehbOKAPQrtLe8ZJrSbbMCGMpPCVg61ExE3m3puX3YdjySK5+5uZYoVZboeW4x5Yb+dZM8k0o82R2KDggHtQBohbWGb92SMDkqcZ9qzZbtVZ/LQjPYmqk0rkfJvVfQiq5lxkkqaAHzxh1LvKzSHogOao9DVlJeSRwx44FViCCQetACUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUoGTgUAFSQRGWRVwefQVYtNPuLqXy4omY4zwK7vwr4eWBDd3o2pH96Nxyw9qAM7SvAVzdW32iSZQAN3lgfMw9RXS6b4T0+0ijuJpPKXPBZOM/WtK78Si3ZIdGdEhjX5A4GfpmuW1HVLq5dp5tzKGyU/hz64oAveINTSwvl/s6KLzUGN8a5DD1xXKXl7f3VwxEjB2O791xipPNYyPLvAYDIAP9aoPdzMQ7ucD3wRQA26aZCDcM0j9iT0qssrOcgHd6jtT72QuA8jKM84A5NVoeu4syr3oAtRQ7A0kgzn7j1OGGzhsZPAI4Jp7tHsRYghDdw2ahJeOUs0YIz90HrQBDIjb3LMrY5wpyAKqOBuJUDH05q2yxvl1Lc9cDgVFM68ZPI4yBxQBVk+9wc49KFRsZZTipoxGyEuOewA4qCXhsAnH1oAbtOSPSm0oJHSkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACl9KAM9K09K02W7dTF94HkGgCW30SZkWSRGMTDhlrpvD/gKTUTuEoXHIEgwDXYeGtGMtnHb3URjdRzjjcD6V1uqSad4d0I26OszOPlzz+R7GgDgrfT7XRT5d0irNCfu7sFh7Gs3XNdlDbIEY2x52sQSPxqpdX013eyyNueMcbWbJxVWQCNHnggZ4zwykZC0ANtdVtnJhu4ysbfxLjinpbwi4YQtLJA3IIBOPrWeLG0uozJHMVlzxGRxVmzku7LiK4lVO4KZoAq6sFt2Ecbnb2BGDWZckpKrow3dcdat6hcGeYtK+9s9+hrNVdxOxRkdqAHlEkAMjKTnOK1NP0f7SzGSaONMAr3zWZAA+QwAHqFro/C1un2qJmSRowwOVXoaANmz0M2enFmtQ8Z6M0R+Y+xrnr+1VW2qDECecnp+Feo+N/EjPpMFol602AP3QQZQ+xFeW3wiZt5klaYnJDDGKAM2Uqp8kHPYkVSvI1Q7lYFT0A5q7PKygoSgY9+pqjMgdhg/KOpAoAhMoKgFRgeg601gpXKqRzU0qBEGwqV9+tREsQx3cdOKAIxwckZoPJzSsNpo3HbjjFADaKWkoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApaSrNlC0s6qF3Z7etAF7Q9NN5Mu5CUzya9U8PeGbSCJTdKwQ8pMv8AI1y/huc6N8xh82NsZVh2rr7XxTEAy2cZRCPmhk5H4UAa17ssbTFndpIF6BzmvPNZubqWcyFW5PAjbIz7VqXOp2l28wnicE/daNun1rLIRsLHvSUHIPUGgDMbV4o3Jmj2ykYPy4z70l5q1t9kC2zFJiMFhxmtnxPBYS6IHuYlW8UcPGcZ+tedzRlMHcDnpQB0fhgPc3h+YbyfuuOPrXR+JJZ7O1eOSIxfLjj7rVwVkzIQ8MkiSDkYNWb7Vr65gCTuXXpk0AVBK8j7Sflz3qaWIQMGD7hj6GqscRaVd8gQddxOcVux26SKMM03qBxQBJotu1xIuB9445XrXpGmadb6VaNLLZO023cQ3y5H+FcjpUC2aiZY2GOQhOQfer19qSXGT9slyBwqnge1AGLrurS3Vw7x7I1Q/KqDkViPdXssZWUbQTknZyfxqzdkwuWj+9nIA5NV5mvr0BcysM8NjA/OgCs7I3yScEei5zStYzeWJGt5FibozDANdZomjWVvCZdQSUzYzlnA/KsPxVq0t1Ittv228f3EBBx9TQBk3Nq0UG5nQDsA3NUDSsSTySaVAOcgn6UAKy55DAnpSYK8cEmkCkk7QSKfGrYJGQKAECkDOBk9BR5ZAy3ApRE5BPQeppMfwg5PX2oAZSU7A5yelIaAEooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAkiTzHC5xmug0myCbi6k46juPcVlaSivcqrjg9/Su+sLOIAB5BBMB8sh+631oAog/Lu81tnr6H3qG7+0riVFU46spzn8Kv6hbwpnd+5lP8AtZR/pWE0zRTMYGwO6k0ASxXKi4VlCA9+MA1anv4fMHl/upVORk8VlXNyCykICp6g069RGtPNhIG3+Bx0+hoAXxFemWIeZGqsRwVPBrnYTvkUbdxp01w8i7WOVHY9qfZHbkgKSPWgC8gWEnzYn6cYPI+lVZ3DAkHaAe45NJJMzSbuS3sc4pZis8YBjKv/AHqAF0+Le4AAKnqT0rpbKwkMn7meHAH0zWVplsHQRLA7vn+E812OkaFJ5kbSW5iTPLEdKANiw8N3H9lC8dCsJGefmBrmtbS3gjZk3QOT/CuRXoGqb7HSdsV1I0G3jyv6g15Rq0yvI2zfu9GNAGYb0tPkynrjOK2odfh06DCQ20rnswLEVz8zxOpMyEv6LwBVBk/iAAX60AaOqa5dX5O8iND/AApxWcwAAZvmzQy4OSy/hRwzcA7RQAHYRnPPoKauM4bP0FPWNS4AJOanVFIKBo19TQAkbqyY+6o7DvTiY8Hhifc8UxwVXbGwI9aZkIMHJNAATn1IHqeBUa7cnOSewHepGVdnYOe3pTcr0Az9B1oAjYc9B9KQ8U8tgYCgH1pnU0AJRTiAOhzTaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClUEnAGSaKljQkArndmgCJgVOCMGkq4HSRdk6/P2bp+BqKSHHTgjtQBBTkXcwB4zSYOcHipUiIYbh+FAGvp6rE6KUw/b0NdckkrWqwmP5D1DDOK5Gwh3lCWfZ0ORnBr0LQibeFWdkmixjryPY0AczrFhc20IYNlDyBurn5JUuAVZTHMOpU9a7TxLfQTK8UJDKR90jBFcEVZJcjoehPegCZkzFhmPplefzFV3upo4zE7b4+3HSp/mWQAOFJ7HoalYq2Fkj3eooAxwfmBI4qYEGTKk59hiluo4lk/cscH+FuoppRgoDcZ6E0AWFVnUlXRX9zjNEKvuCPlcnBNMhB2kFkI+taGlSb5ghj3ehPY0Abeiab5beckoJAz+7Y7hXoXhCW4e6O6Nrsn7odd2R9K5CzjeMgtIImHTZiu+8Fh4nEkF7IpblkHysfxoA2PFtpLLpBaS0FkijIGCB+teFa4jG6YqOR3Uf0r6F8cPcT2CIZ3ZNvImlVm/SvnzxIgW6kKkREds5NAHOSs4lwwx6cdaifaXHOPU9aCxEn3s/XmlZix4Kg+wxQA0qFOeSv5ZoT5TuOMeh5oLEE5Iz69aAo27mYfTvQBIimUd8Dv0FOi2huqhR1PWog+TljwP4afzKRuIA/uigCVnXJAA9uKTymX53PNSDZGvyjD9sHpUTF3YfNknuaAIsCRyAGJ7VIV8sgLg+tPdFiUZkUt6CoXcsML0HegBjMScOTim8beOtIc55pKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiipood4POGP3fegCKrNiu9yvBz2PeoHVlYqwII45qazYpOB69vWgCzdW5jOTkg8EHrUD7VX5TwPXtW8TFLCVmBI/vjt7Gsm9tioPlsrJ2x6UAVEbn96u5f1xVu3lRWVcLIP4Sew9DVWGNuhwe4FWLeNt29R0PIoA63Q7JJGQr8sb9+oFdRqumNb2DYjXfjh0PX61yvhnV47WQpKNueuRkH8K2tb1gXFthTsYdGU5VqAONu5pYpHE6Bkz3NYtxKPOOz7voav39y/nFmU89OazWkTdnaaAJYpImwHLCnzSKq4Ehb0PcVUBCt1yp68UjEfw0ADMWbLHNSDaR7DuajUA8c5qVEdD8ylc96ABQDzHgH6Ve00ES5IDAH34qrG5U5HSrVoN04MbFTnpigDtdOjjMXmJcRJJ/dYGvRPB8sp0+SOQIAe/l8/ga4XTIkNkjSReYw7g4Ir0vwajLpzuiR5xw5PzCgChrzWNxbNAyESr/ABqmCfrXlOvR24Zo8hsdcR/N+deheJmaSVy9yhdc4wwz+NeTeIJpvtDmSdSQf4TzQBkzqkbFY0wP9oc1GF+QkAH69aQvuBOWJ9cZqBmbpuNACseR8uPpS7ARkcD3phJPWkoAUcdKerDOOFHr1phJPXtSpyecfjQBZTL8KckdcU8xHaSxAx2qvnb952wew4pwfj5SFX0JyaAFKfNkjI/SmyMqgYA3UxmLnaOntQVCfe6+lADCc0lKxyeAB9KSgAoopxxjigBtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAoNTQzbcq3Kn9KgpdpwD2oAtTMJCA/LDow7j3pUUoBuGR61WDtjAOMVZhkAXkblPBHpQBrRyB4gT1XoR1/Ed6pXONxP3CfToaj8zZh43JXoPUVI04YYlAIPpxQBBDgNknHv6VoW75I7kdMd6zwwU45H6ginQz+W4PLDPbtQBsvFHOd0TiOYdjwDULyShTHKpGO69PrT45Y5o9ysrH0bg1DMTkbSyP2/+tQBTmErKcjcg6HGapyKWHHX0qZpJFZiTg96qSOWfPf2oAGOQBzx0oDDGGUfhTkkPRsmmttL5H3aAJ4I1cfOuR/snmnSOFG3zSy/3WHSoo5Cv3MH68GnPIX5dPyFABGR2yR71raXbG4mXyNyv/dz1rLgABztJQ9q6rQordnGyBmY98HigDrdLtpI4FW8tvLB/wCWm6untYbWKz/dXUcnqI5GGPwxUnhzw9Bc24e5mdVx0OQP14qtrGlvAzf2fIroP7rhaAMDWrkW6usfkz7u54IrzLWpZvtLeaygE8ADNdR4inmhLrIrZ77mFcXMwkYkodx7lulAEPOwBOc9cVHkjINPZAB8pLH6dKjOe+aACgY70FiQATwKSgBe1H86SigBwJzkdaSlVSelKCOhwBQA6JCTkZGO9IWGeB+JpxLbcLnaaQgxDJI3Ht1oAjpKdgnk0lACUUtJQAUUUUAFKDikooAWkoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACilFO2HbkYIoAZTlbHHUHtRg4zjjpShc9D+dACEcZxxSqGAJWhlK8HoaQEqeDQBNDPsGGXcp6irA2uCICGGPut1qpnpuG09iKlC9Ch2yDqB396AJCUZcFSjjtTEK5IwM+1Pe5EgCzqN4/jXr+NMjQSyDaw3dBnvQBf07YzEHCt6N0qe8teCY2Lf7JPT6Gn2dq0pEcoRZRwDnGfxq/Ppd1bpv2kqOo6/lQByspfPBJINNdyR84BP0xW/LZxXALQBVl7oTis6e3aEkOpA+maAM5e5UGpPKLAkqR64NTJHsbK8qfTkUsiKDzhfp0oAiZPkyJFb2I5FQHI7CrJIjw24H6VXkIZsrx+GKAL9kkrgbFYr3ArsvCqLFdKZhJGndgua5PRI/MmTc+z0PavTdHmuEt9izxup/55rn86AOwsfFTWEHlwMtynQCQ4/Q1zOv63HqEhD2Zgc/8APMjJ/Ks/VbViSxUc/wAWSv6VhX9zLYx5Eakf3s5NAGTrmwOTvkGP7y1zkhVny6ll9RU2o3z3MpJlYjNVWkwvBGaAE3DPylxTXB6k/maQHBzRwTycfQUANpwbAIGPrSUlAD8ADg5P0pNp9M02nYxQA7eSNo6egFJsbpilRWI4OB607AXluaAGcL0J3e1BxjqSaXGQWOfoBTACTgDNAASSOTRTgrZ+UZo2k5OOBQA2koooAKKKKACiiloASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAcpweRmp4/l+eMb0/iQ9RUKAEEE4PagZRupB9RQBsJpwvIGn00iRgP3lufvD6etZuwkhRlXX14I9qltbp4JldXMcq/dkWti5e31hczBbbUQOHUYWX6+9AHPHrhxgjr71II028EMp7+lJcJJFOVnXDDg570wKVfjkUATiBk+8N6H0pxRRnB3gDt1H1oilKHPOP5VYdQ/wA6/MP9ngigChI6lfWltkO4EggHoRSmEF8kkL9K19Nsbg/PEhdBwRjIoAljWUxL5odkHRl5Ire0y5lVAgmJX0fmiy00suXiliJ/jQEgfhWjb6Ncj51VpYuTui6j6igDIvrORpTMqpg9duDVZbaOUASKw/2s8V0U1jLsJMKzL/eT5WH1FVhp8gPmWrDI/hJ/oaAMuLTY4zuEDgHuOQaydcWOA7dmwn/ZrsBE7RnzbJg/domxn8K5PxFGWc7Hmx3WXt+NAHP4yeRvHsaRVUSdwPRhSGPHTdVuyhkk4KZHrmgDX0pzJhFhjPuBg12ujvLaRkwzzwMB0GCDWPoPk2UOZQy8fxIHX/Gl1TVEckQxqCP4kyP0oAu6xrVw+RPcCRfQjFcZqt0XYlZSFPbOaL+/umBVhlfcViN87kk4+tABK5ZsnH4DFOHzL9/8OlMYDHD5/Ck7dOaAENAAPU4pSxYc9BR0PIoAbTuDwBzSHGeOKVVJ6A0AIRg4oBAPTNTw28sjhY03E1qQaLcOVDxqCf4RyaAMhF3YznaO9Wdibfl6e/NbkmjW9lFvvLiOM44TOWrGuJfNfZb4K9AO9AFaUYwCT9BSBCpyQAPTNXXgECZndFJHCjk1RZt3IUlR60AS5CrngVA7gt3K0GQsOgplAB3pQMjGAPek/nQST1oADSUo56nFGKACkoooAKKcF+XJ4FNoAKKKKACiilBxQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUALSU4DIyKFbFADaUgjqKc4HVeh/SlRsAgjK0ANzxg0Zz1PSnOnG5eV/lTO/WgCQqQODuWlSQxnB+dabvwOOGHcd6QZOSB9RQBJNM0gAZt4HQnqKanYHK+hpV2kHjjuO9PiVSdr/ADJ2NAEyHd1Xkd171KshwCBgjuB1/CoBEyENE24e9TG4fbiSPn1xQBZifzSF2g+prufDFnPbhbhF+U4yU5GPcV51BcMkwIOVz0bqK7rw7q/lsBFM0Eh6g8o1AHqmkJp9yofP2G56bwN0b/X0q9eaBcEebDEFkH3ZrYgg/UVylnLPKRJBKiy9wOA39DXb+FLnfIqi4S2uf+eU3yo30NAGGmmzGXfdJLG3d1j6fUd6bf6RExWR4I5UPSWJSp/H0r2CO3F4ojVXhuCOVKiRW+hFYOp2f2F3dLi23EfNDIpQt+fFAHn02hRC1zDKnTOyVdpH0YV534wtRBGweAkc5zhsfiK9M124t33+TMLaTvGVyrfQ15b4njWUuscm1+pUHg0AedSMBJlEG33PNT28zRsfLYrntmrUenI7sMurZ/u5q0NLZVys6H1GSP50AFldy5xuYn2IFWbiYBD5rPuPTABqhNaLj5wpP+y4qjMwT5QGP+9QAX0m8kIzkdeazsnOe9TPu6hDH754q5ZSiEjzYmcd2QA0AUkjMg5RyfXHFPWJwSoyPw5rsbLUdBcBLlrkE9gAv61qJ/wiWzdJ9qQ+qsr0AcRbab5xGRK2fQ1oDw7Kfux8f7T5roLu60VBusJpScf8tAB/KqX/AAkN5EpW2SIr0yRQBQj0CQAgWasfUvUE+mTW+WlEaKOimnXupardN80zBf8AYGKzLhJTgyCSRs/xEmgBHuJY3whGP9njNOGp3QBWJxHnqc81WkEgH+rCr6niq+3sDk+gFAFjCu2+7nLH0ByTUov44U22tuin++3Jqiy7epGfQUmRjpQBIWeZizNlj1zVhbX5Q00gAPQE1BGpfHIRfWp9kSrubLem49aAIJEjXO16hqVzuOFA2+wqNsDjBoAQjFFFJQAoPqM0E5PNKqljgU4Iy8kDHvQA1QPqaQilKkDJHFOXGcKNxoAZQRjrTwCCQDz3prAYGOfegBtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAoOOlJRRQAU5eOQeRTaKAJVOWyuR6imEDPFJQTmgApwfA9x0NMp6gEccNQBIoV8FeHp7R7snGMdxVcEqfpU0bc5Vtp9KALdqjsNvbtU7xSRY3qdpq/oot7thHcLsbs6n+YrobnR5LW3Em0XEB7j0oA494kcDeCD0B28itnRtLbIMZG/sM4NTJDAVKg4U/wAL9vxqW1mn05gFIkg7A84oA6bTLwWpEOoWs6Hs65FdHbXwhxskaaI/wSjB/Ouc0/Vo7yEQi4iRuuybkfnXQabdSwr5V/BGYT92ZOR+NAHaeHPEdsdi/apYXHRWbgH2rr9R1ua+sCl7FFqNuBhZOC4/Ec15dc6Rb3KCRnCqeVljOf5Vk6hHqOkr5ltcPJF2dG5/GgDR8RajpVrM/lmeM9SjDOK881/XbSYkMjsvTO0cU7W9YkvMi7nYt6uv9RXOhI5pcNIqnoCelAEaXMPnhoXIz0J61sLcyyQ7SLaYep4NVzpgcZjRHPrGev4VTmhu4DtijYZ/h6/pQBWv7GSVmOI0PpmsW4tJ4m+YHB6EHNbu6cPi4gkH/AasvaCaMeWs6n0agDkwZBgNux7jNSeZIo+WYgenSr99byxOQ2SOnFZ/lpn5t/4UAROWc5Y7jTR196c4UH5C34im0AKGYcgmpYrqWI5VuffmoKKAL76tesu3zsD0AAqs91O5y0rk/WoaKAHM7N95ifqaNxAwDxTacqlj8ozQAlAqwLSQJufCj0NQMMMRnNAD1kweST7UGXjAApIlDdsmnGLkkj6AUAMyxHXimVO0TAbnG0dhiowo3YJ4oAaM9s1Mts5XLfKPepI54ovuIN39480vzTNmQk/7IoAYkaKw53fSpX+UYVcMe5qQO0eFiVR7jmq7y7SSTlqAI3UKPnJJqW3t5rjiFCFHVj0FMiAkfc+W9qvvKxiCEYjH8CcD8TQBSkRIwQDvAPX3qsTk81NIQGJPJ7DsKibPU9TQAcD3ptFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFOXGeTgU2igAooooAKehXOG6evpTKKALAClSJOR2cdqYrbGwcMtNDY+6T7g09UEg4+Vv0NAG3pLRs6EZIz17iu+065ngtxnDREY5rzzSphDMq3Csn+2vb8K9J0aVordW2pNCR1UZB/CgDO1C1hm3S2q7GHVCODWOXjQ4ctE3pjIrtbiytro+bYubefrgHg1nXm14/Kv7RfMHSWMYz9RQBzbQeYNyeVJ6bTgiremT3sMmLS52MOqM3B/OoLnT8tmFwj54B4zUaOw+S5iJK/xDrQB2Wna5PDhb222MeskTbf06U7VtXDQt5VwjKRyHGD+lc5a38cS7T86ehNZeuzRSqdkJHHY0AVNSvkd2EoHPdTWfbPbrIMuMH1rJnJzxxjtmiPeeTz7d6AO3tnUputnhDY6qxFPe7uDgSSq2Pzqh4cl2YGQv+y4yDXRXE8IUNcaZE4x9+MkUAUVu5Jo9hlLKOisBRFIqNiSMIf7yHmpkubJ8+XEFb0Yg1MLu2iBzaxsfagDPvbGO6jLC5ODzyoyK5u60nYWZJldfTaQa66bV7Qgq0SRH6Vi386yAtA8hHoE4oA5O4jMb8ZFQnJ5NW7wStKd2fxquVYLjcMemaAGY4zkUlLSUAFLigDNFACVYtmAbkHj0qFVz9Kt2yjHylmOewoAnld2RRs2gDqxql8i/w7j7VolNw+aKVvxFRtBkcLsH+0c/pQBFC7yZWOMKO5Apz5jzhwGPocmo7iNUX77E+3FVty9wxHpmgBXOTl2Lt9aRcNnI/wAKd80h+Rdo9hUq2205djnsB1oAgEbE9OKuwrtTlSf0zT4bSaVgVXavqxp88cUCf6xpZD1x0FAFabcy4wI19BUYiAONpP1pryMp4wDT4ZmzgDJoAkRdnLICPemzSmT5WzjsFFXoLdpY90pEY9+/0qreuiKVgXC92PU0AUd20/KMe5600nJoNJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAtSQgk4DgH0PeoqWgDSVzHgSoQexU11Hh7UlhZfKlZT3RuBXHQ3bKu18OvvU8VwFf5Mj9aAPXbeeK4IK7Q/oPlb/A1dF7EFMdxGso9JBhh+NecaVqfyqshYZ6FT/Suv03UorgCOYGUgY4PI+lAGjfWFpcwb7eFlB5whBrnpNPkR8xuyMPWugiMUD7rO5QsOsNwuwn6GnXOpafKhW9gntJT/GvzpQBzM8Z2EXSRt/tBcfyrm9Uh2kmLafo3NdVqMds4JgvwwPpXNXVq/mH542HvQBzVwGLZcAH3psfzH74P14rYubByMhImP8Asms0wtC5DoCB1GaALVtI8JUuFdR+ddVpt3aPGA8k8Z9R8wrBsZI0x+5Qj861YtRiRfkhi47AYoA1JtOSdTJBIj/RgDWXcW9xb5zFIR9RUqau0gwLZGHrmqs94GJzAyn/AGTQBUubhv49yH0dc1l3FznIAyeh2titC6njYf8ALbPbnOKxZmZm4wPrQAjHJ+6R65NQMoBOGFSsjFcEq34c1F5MmM7Gx9KAGDHein7QB82RTWxn5SSKAG0oGeKM8U5ELHjA+tACbTnA5PtV6wTY4LKR9eBT7eCDgy3DZP8ADGn9astFGAPKRwPV2oAuG5gEYAJJ9FHH51RuWkkyV2xp6Hinww/P80gWriwQgcBpX9W6flQBgvCzNjIb3qRLTC53KT346VvxaZNKNwjRR1y52gUyS0SIgNJHKe6r0oAyo0dmAUnHooq5FZyE4A2sen8TGtG1tnncBFwPpgCur0KK3sgClv8AaJ/phR9TQBgad4S1G7jMhTyoR1aQ1Q1uzsNOyhm+0TAchfuiul8SaldSRsLu8CIOPIh6/pXnWpS+dLhVIGehOTQBXdvPlOAEHoKtWVs80gS2jdpD3NR21soIaV8f7K113h3RL275t0EEH8UrcZH1oAqjSI7OIPqM+9+0KHJrntWcO/C7FHRfSu31ttN0yEwxP9quuhI5ANcBdO00zMRyT0FAFailwc470pUg470ANopSCDg0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFLSq2OwI96euxjjGPSgCMDJxU8Q28HBX0PBpwtXK7kAde470KNxwjEP/degDVspIywUHB7/AP6q3YYty7o3bcO6HBH4GuQ+YEb0I75rVsNTmjG3cki+jjBH0NAHWwareQr5c8cV5F/tjDCn/wBqWxX5VkgY9UkG5awW1NGjwwKkdA4yPzrOutUIbCsCPQndQBtahcRSAmNEDf3o2x+YNZS6ncRtgnI9GQEVkT3Xmc+WPqppIrto+QXx6MMigDdj1CGRv3kK++3ir0UGl3OBLJ5Tnpu6VzJuFlxiMK3qKkX7WkeVIYfSgDpZvDLMN9nIJP8AdYGs250i9i4lt34PWqdnc3sZ/duU9BnFaq6nqO0CYh0+uaAMpLeVHO5WH4kVbHkbfmlkDjt1qWW8hfO8FSe5qjNg/NG4oAkmjLAeXI59Mx4qi9scnzRJn2qcXF0EwssuP98VVkuJd3zyyflQAhjjU5RpN3tUcskw43N/wI1KJHcEKyn3JFQyo4OXZCPZs0ARFSTnYWPXpUZDA5KAj0xUu58dG2j3peOwJ/GgCMCNhypB9AKcJHXgRrj3FSEDZ9xg3vUBbGM5H65oAkQSM/3lQ+1TpDIxByze/Sq/njGBn8qcjFujEfWgDQijcNgEj36mtaztZmO4Lk+rNisKO4MfCt/3yta2myqSGlWSTnhd3FAGl5EsnEnlsfQEmpY7S5HKwqi+pA/rUn26cpttoobdfrzTobaQgPdXCOx9WNAEgf8AhwZPx/wqdo5HiO4SJHjop4/E060uYIWGQJW7Kq8CpNQ1iMptaJj/ALOeB+FAHMazOVVkhiAHr1Jrl2WXzPmBUGupvbx5t3lxIoPVqxxuM4wQWz36UAXdF0yWRll27IxzueunuLhkttgnkkXH3V4FRaBFC20ztJcuOkcY+UUviS8eJCiCK3GOFQZY/jQBymqzOHI+WIHnaOp+tYYBZjtPNT3JDyscs7E9KaylF/eYUegoAYMrnZ17saiBIp7Et0ztpnegApKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKcBnp1ptLQBZt7ho2Ab862LdoLjaJokkU/xDg1z4b15FSQStE4IOBQB1knh9Wi32kssZI+5IMj8DWLeWFxat80atjtWroPiO6tGAEgaPujjcprsYr/TNWj23NrHFIR1Xp/9agDzAzjaR86HPQ8iqcrbm7celdxrmhWa5MLtF/48prkryxlhJICsvqpoApKQOozVuHyH6kxn2PFVdxHelCluaANFIwjBkkRs+vFWluMcFWUjurZrLSNkAycD35FXIULfxRn04oAtpNK4+UCTthlFJJKyfehZD7E01YHRgzY2+q1pWrQEBZF3H0zg0AZDec/Qlh7ik8ogDevv1IxW9JZW7/6uJ1b1xxVaXTLnP7uTA9MUAZRVxyqo6n1FOzIAdsQBp89rdx5BYEe3FZr/AGgE5JP40AWZHcf6yBfyqAgsflXFMDSNw36mlYHpnH0oAPLYA5Kg96FUsQCWP0pAiqchiT609CVPXGfagBzwpj+I/VqjSANnC5/GpfMz98D67c5oZ7cfeD59sCgBgtcEFhgfWr1vGjL1wB6mq8RRmAQEZ/vGtC3tlYAkx8dSxoAabfc3yNu/3VxVyztQrDepPP3QcVNbLbKcNIZW7Ko4FbEQ2RgkGNfQAA0APtorWNAZXWH2Rdx/M0l1PYIp8pJXP96RsD8hVS6mgJwkTOe+05/Wo4bWWdwYkWL3Y5NACtczFT5cbRoffFVjKEyWgZ29zxWo9lHEubm6y3ucn8Kxr91Z9sETv2yepoAr3U0tx8gCoP7qdqtaLpBu7hVVC5J6DnNaGhaG95IDdbbeAf8AfRr0C21LT/D9ps0u3HnAcyMMHNAFN9An07Sy8jR2UOM5bhj9BXluuSo9w4hLyrk/O3Fb3irxFcahMzXUryDPQcAVxdzK07E5x7CgAZiBgFQemBUBGDkDcfVjUqlcHIyffpThlv8AVpj3NAFZ1bH7w4HYVFkjNWpAFOSwJ9fSqzHJ7496AG0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRS0AAxnnOKf5ZP3fm+lSIP9kgH8jUq7B6qfbvQBDHbmRcryfSnLGVIDHH1FWkZ1AYoJFHdeoqUXMMigOfwYUARR2rDDbG2/wB5a1LV5EAEcquB/C3BFVIJoYpBiR0HquP5VpmFLmMNG0ErDuPkagBrXMrDa+5R05qs8QIwD/3w2ahnSa2J3LIo9Qc1Ue6c8Fgw9cYNADLy2VSx3fN9KpLjP3iKsSzyEnEgI9KqnrmgCaNmQ5DZ+hqys8bDEluVb+8DiqFWYQXx84Pt3oAuxTlWAQuPYmtGJiBlo356HANZsTADbuY57FetWYQc5RpE9ADQBoi9aPGdx/3auQaqh+Voyx9ziqlvI8ZBaQgerIDVv7VE4w5gPuY6AGXvlTISYGHfKtmuduoF3nyy270IrUvXUqdhiPsoNZwuJ1yBHkH2oAqmPaPmVseoHFQuMdAxB7Zq+khdv3iEVK6bkwOB9KAMhUPO1D+BpywzduPqasGKVWOwZ9s4zSOsz8NFjHoaAIGWUY3P+tKBjrgn6VOsD4+aMn3zipY5I4T8yEt7YNADbaF3PyCT/gK1ofZWwC8cnr8zYqBNSONu+RV9qu2t9ZgjzYJpT33NigBI5VgI2x4P1zVpJpZDn7PLIevI4rZ0/U7FFHlWFvH/ALTAsasz3sN0uCZGHpGu0UAYf2xUI85CAP4V4pzamHAEMQUD0rQ+z2rNnYiA9NxJNXLeCFRlPLQ/33HT8KAMaOGab7m/5uu1cfrWnpWivPKoaXb9Oa0IvsjPsMskvqcYA+grYh1DTrCMeTbPLMB1dsD9KAHtplrYW298yMB0Jx/9euX1W9eXcsaAL6KNo/E1Y1rVrm4BMrRwxnoAf8muRvbjf8skrFPReBQBT1JwzMoKH2HNUVhkkfaiNIx/hQcVoQywKcpb5HuetaCalMsRW3jRFxg7Vx+tAGUui3IAe42Qr/dJ5/Gqd5sQ7Y5DKfRegqxe3jyuQ8jSHPTtVcMqnEaB5PagCg4PVuvpUdWp0YEmUjPpVYnJoASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKeqEjIGaZSgkHIoAmhdlOFwR6MKuRhZFJ8sqfQc1QEpz8wz71dtJYRjOUb+8Of0oAtQWiSn93MYX7ZHFSz6VdIheW0W4T/npEefyq1CHK7ozHMMelW7bUzAeA0TDt1BoA5aSPy/uFx/sOuKWOcK3zKAw9DXate6dfJtvrdSf74HNZl7pVjIC1pc9vuyf40AYrX8sajYxA+lU5btpPvKufXFLe2r2z4YceoORVWgBzNuOTSrt/iz9aZRQA8qMZDA+1EagsAc/hSAEnirlmAhDN8pz3oAI0ZWwjk+xFXLZ9p+eN/qDWpZSwSgK8eT6g1qR6JJMoZY5dh74BFAGbbKsq4RCSexxUjWwXmW2YD2Faw8OxxrkzFG/wBpSKryWDRE+VKrj2cigDLMVsGwsssTf7S5qYRQt/rbssPQf4VJNazDlgV992aqSwS54nJHsKAI7uKzT/VnJ9SaoKMv8h49xxVx7UD5nZh75pixwdHn4HYZoAQW0jLnKY9Bwaj+zHnKHj3zU3+iK3EZc+u/FP8ANiGNsW3PfcTQBU+zuxwqP/31gUn2SROhiX9TWnDMg/55H/eFXEvHHEYjb/cjoAwY7SdmPysR/eK4rQg0+IDMryluwWtaJr2c4WAj3C1tWGltw08SZ65kkx/KgDCsdIup3H2O2mdT0LHArrdM8N6i6gXM0cCdxGu5qtpF5KZa7hjUdAGJx+FB1O6xss7iaQ/7C7RQBoW3hYf8sra5lY/xysEH5VJd6FYWcfmanf2duAP9XG+5jXNXcmoSn/TLqUZ/gDEk1SbTpXBlYJCp6vOwFAGpdalo6ZTTrSW5b/no+QKxriSSZyTthX0Hao53ghXbJqAb/ZiHH51mzXlsoOC4Hr3NAEt4luoOGZnPUnk1lvGmdzKT9f8ACnyXiMcQhuO4HP51WedicLHuf1JzQA8ldpKxqB6v/hWZeTNO21HZz0+XgCrExZ/9dLk9kTmnxRFUyQqAetAFGOyZuXPHtTpGSFCqHj2qW7mwh2ksQOvYVlPNk5OTQA2ZifQD681DTmbPYD6Cm0ALk4xSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUuaSigC5aX01swKHIFaX9sxTLi4h+b1FYNFAG01xGeYpSF9qaL514by5B78VkDinByOvNAFy7lSUfcYfQ5FUSMetSBx2LL+tIHYnH3vqKAGLjPJwKsCCNvuSc+9R4LD7mPcUoVgMGM/WgC1HGikb9hFWRBGRlGI+jVnKQpI2kZ9ea0rOWDKqy5PqKAL+mQusgCDfn3wa6y2nuoYwYlmjPvgisbToYiQUjbB7kZrs9H0lrgARvag+juQf1oAxpda1BVIlG7tllrIurpp2yQqn6161b+BdSuVDwfYd56bJAf0p1z4D1aJD9usYpVx1VVzQB48EVh81yE/4FUTpHn/j4DCvRr7w3aQEqbGdHHGAoNc9qGiW4zts7lfcYFAHKLDat99nHuOamWDTox1eQnsVxVx7YRZVXljx/fUUiWkh5W6hP+8KAI4vsn8FlHn1wacVtiTvZY/QLHUjLPGMefbED+6aha3E2MyRZ7ndQBJFFZbvkLSf9s607eOLA/cP+LBRWQtlOo/cyRn3GTR9k1PJC4b0IU0AdGB8vyxRRj/ZcsajMrRt0JPqaxhbawq4EhQe5C0ySK9TPnXy++Gz/ACoA2pbyKNQ80z59NtVZdenKlLczCP2GKw5nw3z3WfdulQNfhPuv5mPQHFAGjNqcxYn94M992TVZp5Jm3P5u335NU31hgcLGoYnj5cmlN7dTDncqnuRigCWa5jTISD5v7z1VLlyTI+F9hTZJli5cjd6k5qjJfjdnfn8KANEfOoWGORsd3OBUZhbOHcE/3VOMfjWY+oSngO2PToKrPPI4wWOPQUAbym1tzmaZQR/CvJqrc6rFk/Z4izdAzn+lY5pKAJp7iSY5ds+w4FQ0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAoYjualS4kXjdkehqGigCz9oDEF0/75qaOW2OOXU1QooA6fT9S+zECOdsegaukstcknVQWX6lRmvNKcrsv3WI+hoA9lsr+5jIMF7JE3+zxXTWPifxNaJ+61eaVAOFcAivnxL66T7s8gH+9ViLW9RixsupOPegD6MTxXd3YCajCjMf4gADTZolvMtBDIc9Bsz/WvBbfxfq8Bykyk/wC0ua04PiPr0XV4WHvGBQB6rfWWqRxN5dpHtx/FEorjdTtrjeftFnEPyFYqfFDWRjdDatj1U1M3xSv3Qq+laY+e7Rk0AL5EKn95acdytaFj/ZUagyRXob0XFcnqXjK7vSSLS0hz2jTFZh129PR1X6CgD1I3Nttxaabfynp8x/wqnci95ZdMeNe5mkxXnJ8QarjAvZlHorYqtLql/Kf3l3M/+8xNAHa3NxOpIaOEe6/NVM3KHIlkc+wYKK497meT78rn/gVREk9STQB10l9YIDuWEt7vuqjd6xAQVijHtgYFc/RmgC4+oSEnYAtQvcyv1dvzqCigBSSTkkk0lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Compare this video clip to the apical four chamber view of normal cardiac function and note the collapse of the right ventricle.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_55_35711=[""].join("\n");
var outline_f34_55_35711=null;
               